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INTRODUCTION 
The ovaries are paired oval structures in females, developing from the gonadal 
ridges, and located one on each side of the uterus in the ovarian fossa. These are very 
complex organs in terms of embryology and histology. It undergoes cyclical changes 
from adolescence to menopause and gives rise to different types of cells, each of 
which has the capacity to produce different type of tumours1. 
Due to constant endocrine stimulation and subsequent traumatic insults by 
ovulation, these are the primary sites for tumour development. Different types of 
tumours tend to occur in different age group. Both primary and metastatic tumours 
occur in the ovary with variable histomorphological patterns.2 
Ovarian cancer is one of the most common neoplasm in developed countries, 
ranking 7th position  in incidence and 6th position in mortality3.It constitutes about 
6.6% of all malignant tumours of the female genital tract3.In India, incidence of 
ovarian cancers come next to cervical and endometrial cancers among the 
gynaecological cancers. According to National Cancer Registry Programme of Indian 
Council Medical Research, the proportion of ovarian cancer varied from 1.7-8.7 in 
various urban and rural areas, it also showed that recent increase in incidence. Both 
Chennai Cancer Registry and Dindigul Ambilikkai cancer registry showed an age 
adjusted incidence rate of 6.0cases per 10, 0000women4, whereas it was 16.23 in 
United States.3 
Ovarian cancers area heterogeneous group of neoplasms of three main 
subtypes: - Surface epithelial, Germ cell and Sex cord stromal tumours with wide 
morphological variations. No age group is free from the tumour. In adult age group 
surface epithelial tumours are the commonest neoplasm constituting 65.5% of ovarian 
neoplasms. In younger age group, germ cell tumours are the commonest ovarian 
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neoplasms and constitute two third of ovarian tumours out of which, one third are 
malignant. Sex-cord stromal tumours can occur at any age group and are usually 
functional in nature. So the determination of various histological patterns is very 
important in diagnosis as well as prognosis of ovarian tumors5. 
Ovarian cancer has got a poor prognosis among all gynaecological cancers. 
The overall 5year survival rate is approximately 45% due to late stage at 
diagnosis6.Unlike cervical cancer, identification of high risk population for ovarian 
malignancy and ideal screening method is not available. 
A number of non neoplastic lesions can occur from neonatal period to 
postmenopausal age group. Most are functional in nature and resolve with minimal 
treatment. Some of the non neoplastic lesions like massive edema of ovary, stromal 
hyperplasia, large follicular cyst, pregnancy luteomas, and granulomatous 
inflammation can be confused with neoplasm clinically, intraoperatively or on 
morphological examination. The main aim lies in distinguishing ovarian neoplasms 
from the wide spectrum of non-neoplastic lesions. Despite the new techniques like 
imaging and genetic studies, the diagnosis of ovarian tumour is mainly dependent 
upon histopathological examination. 
The present study is being undertaken to review in detail the different varieties 
of ovarian lesions in and around Tirunelveli and assess their characteristics with 
regards to incidence, age and histopathological appearances. 
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AIMS AND OBJECTIVES 
1. To determine the nature of ovarian masses presented to this Department of 
Pathology, Tirunelveli Medical College during the last 3 years. 
2. To ascertain the frequency and distribution of ovarian lesions among various 
age group and to correlate them with the clinical features. 
3. To study the histomorphological diversity of various neoplastic and non 
neoplastic lesions of ovary. 
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REVIEW OF LITERATURE 
Embryological development of the ovary: 
Gonadal development occurs slowly in female embryos. Sexual differentiation 
of gonads is recognizable by 6th week. Ovarian differentiation is a passive event 
which occurs in the absence of testicular differentiation. The occurrence of familial 
XX gonadal dysgenesis, transmitted as an autosomal recessive trait suggests that 
autosomal genes are essential for human ovarian organogenesis.  
Gonads appear initially as the gonadal ridges which are formed by 
proliferation of epithelium and condensation of mesenchyme. Primordial germ cells 
first appear at an early stage of development among endodermal cells in the wall of 
the yolk sac close to allantois, and then they reach the gonadal ridges. Before it 
reaches the ridges, the epithelial cells proliferate and produce irregular shaped cords 
called primitive sex cords. Sex cords differentiate to irregular cell like clusters. 
Surface epithelium of female gonads proliferates and forms second generation of 
gonadal cortical cords, which permeates the mesenchyme. In 4th month these cords 
split into isolated cell clusters with each surrounding one or more primitive germ 
cells. Germ cells develop into oogonia and surrounding epithelial cell descendants of 
surface epithelium form follicular cells.7 
Anatomy of the ovary: 
Ovaries are paired structures, oval almond shaped, located one on each side of 
uterus close to lateral pelvic wall. They are attached to posterior aspect of broad 
ligament of uterus by a double fold of peritoneum (Figure 1). Each adult ovary 
measures 4-5 cms in length, 1.5-3.0cms in width, 0.5-1.5cms in thickness, prepubertal 
ovary measures about 9-17mm in length, 4-7mm in width, 2.5-5mm in depth, 
postmenopausal ovary measures about 2-3cm in length, 1cm in width and thickness. 
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The mature ovary weighs about 5-10gms whereas weight of the atrophied 
postmenopausal ovary is 3-6gms.5 
 
Figure1 Anatomy of the ovary 
Vascular supply: 
The ovary receives its blood supply from the ovarian arteries. The ovarian 
arteries arise from abdominal aorta and reaches the mesovarium where it anastomosis 
with the ovarian branches of internal iliac arteries (Figure 1) 
Venous drainage: The right ovarian vein joins the inferior venacava whereas 
the left ovarian vein enters into the left renal vein. 
Lymphatics: It accompanies the arteries and drains into external iliac and para 
aortic nodes. 
Histology: 
The ovarian surface is covered by the germinal epithelium which forms the 
single layer of cuboidal cells. Beneath the epithelium, it has got outer cortex 
containing follicles and inner medulla containing stroma and hilum. All the follicles 
are initially primordial in type. During a women’s reproductive age group,5-10% of 
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these primordial follicles will undergo some degree of maturation and changed into 
primary, secondary, tertiary and Graffian follicles which will releases its oocyte at 
ovulation5(Figure 2,3) 
     
 Figure 2 Histology of the ovarian cortex      Figure 3 Histology of Graffian follicle 
Functions: 
 Two main functions of the ovaries are production of ova and hormones; both 
the functions are controlled through hypothalamo pitutary ovarian axis by endocrine, 
paracrine and autocrine pathways. 
Risk factors of ovarian cancers: 
Familial predisposition is noted in 5-10% of cases. Majority are associated 
with mutation in BRCA1 or BRCA2 and DNA mismatch repair genes. Syndromes 
associated with ovarian cancers are Lynch II syndrome, Hereditary non polyposis 
colon cancer syndrome. Individuals with Gonadal dysgenesis are likely to get 
gonadoblastomas8. 
Risk of ovarian cancer rises sharply after 40 years of age and parallel with 
gonadotrophin levels. Nulliparity, early menstruation, late menopause, ovarian 
inflammation are associated with increased risk. One theory says that these events can 
break the surface epithelium either by monthly ovulation or inflammation; these 
repeated traumatic insults can be the cause of ovarian cancers. Women with reduced 
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ovulation by oral contraceptive use, multipara, pregnancy and lactation showed 
reduced risk9. 
Use of clomiphene citrate, long term estrogen replacement therapy increases 
the risk of invasive cancers. Dietary factors can also play a role-cheese and meat 
intake increases the risk whereas higher tea and tomato consumption reduces the risk9. 
Clinical features:  
 Symptoms of ovarian cancers may not be present until the late stage, 
afterwards abdominal pain, abdominal mass, and ascites can develop. Precocious 
puberty and menstrual irregularities were seen in functional ovarian tumours. For 
early detection of ovarian cancers, serum biomarker assay, transvaginal 
ultrasonography and genetic studies can be useful, especially in high risk 
individuals10. 
Spread and metastases  
The most common metastatic sites of the ovarian surface epithelial carcinomas 
and germ cell tumours are   contralateral ovary, peritoneal cavity, para-aortic lymph 
nodes and liver. With intra-abdominal spread, ascites and omental deposits are seen. 
Mucinous and endometrioid tumors have less tendency to early and widespread 
peritoneal involvement. Yolk sac tumour and choriocarcinoma are commonly 
metastatic to lung by haematogenous route8. 
Classification: 
The main purpose of classification of ovarian neoplasm is to facilitate the 
communication between different workers in the field of ovarian oncology be they 
pathologists, surgeons, epidemiologists or radiotherapists. 
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In 1967, Novak formulated a classification primarily based on two factors 
benign or malignant and cystic or solid. It has the advantage of being simple but the 
borderline tumours fall into the grey zone.11 
 In 1973, World health organization (WHO) formulated a classification based 
primarily on histogenesis. This classification system was updated in 1999 and 
subsequently in 2003.12 
I. SURFACE EPITHELIAL – STROMAL TUMORS 
The generally accepted view is that most of these neoplasms arise either 
directly or indirectly from the surface epithelium, or serosa of the ovary. It accounts 
for about 60% of ovarian neoplasm and 80-90% of primary ovarian malignancies. 
Mean age of benign epithelial tumours is 40yrs but malignant epithelial tumours are 
common in perimenopausal age group3,8.  
Molecular pathogenesis of surface epithelial tumours: 
Surface epithelial tumours are most commonly associated with genetic 
mutations. Recent genetic studies signify that each of these histologic subtypes is 
associated with distinct molecular genetic variations. High-grade serous and possibly 
endometrioid carcinomas most possibly arise from invagination of surface 
epithelium(inclusion cyst) with p53,BRCA1 and/or BRCA2 mutations. Low-grade 
serous carcinomas probably arise by activation of the mutated RAS–RAF signalling 
pathway in a stepwise fashion in an adenoma–borderline neoplasm–carcinoma 
sequence. Mucinous carcinomas are associated with mutations in K-ras oncogene; 
low-grade endometrioid carcinomas are associated with endometriosis via mutations 
in CTNNB1 (the gene encoding Beta catenin) and PTEN13. 
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The most important group of neoplasms, which arises from epithelial tumours, 
are classified according to cell type as serous/mucinous/endometroid or clear cell, 
according to pattern of growth as cystic or solid, according to atypia and invasiveness 
as benign/borderline/malignant tumours. 
A) SEROUS TUMORS: 
Architectural and cytological features of serous tumours resemble that of tubal 
epithelium, this presumably arising as a result of mullerian differentiation along a 
salphingeal pathway5. 
These tumours comprise 30%of all ovarian tumors. Out of which 70% are 
benign, 5-10% are borderline and 20-25% are malignant. They are more common in 
4-5th decade of life. Bilateral tumours are seen in 12-20% of cases.3, 8 
Benign serous tumours: 
Three basic patterns of these tumours are serous cystadenoma, papillary serous 
cystadenoma and serous adenofibroma. Serous cystadenomas are predominantly 
cystic with smooth inner surface, whereas papillary cystadenoma shows papillary 
excrescences in the inner surface. It may be confused with rare rete cystadenomas but 
the latter have the hilar location, surrounded by the layer of smooth muscle and 
exhibit shallow crevices along the inner surface. Serous papilloma appears as 
polypoidal excrescences on the outer surface. 
Third pattern is solid fibromatous tumours, they appear as thin walled cysts 
containing polypoidal excrescence embedded in a fibrous stroma. Surface papillary 
adenofibroma should be distinguished from surface stromal proliferations which do 
not form a mass lesion5, 8.  
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Serous borderline ovarian tumours: 
They are also called as Atypical proliferating tumour or Serous tumours of low 
malignant potential. 
The mean age of incidence is slightly higher than benign tumours. They are 
bilateral in 26-36% of cases. In borderline category, at least 10% of the areas showed 
epithelial stratification and complex stromal papillae. These tumours are separated 
from carcinoma by the absence of destructive stromal invasion14. 
Gross appearance is similar to that of the benign tumours but, inner surface showing 
more friable and more exuberant papillary excrescences. Cystadenofibroma of 
borderline malignancy has solid, tough, rubbery areas varying from white to yellow in 
colour. 
Microscopically the most characteristic feature of borderline serous tumours is 
a complex hierarchical branching papillary pattern of growth. The papillae are lined 
by stratified epithelial cells with nuclear atypia. 
Peritoneal implants: 
The serous borderline tumours are associated with implants in 30% of cases, 
which are divided into non-invasive and invasive types. An invasive type shows 
invasion into the underlying normal tissue as micro papillary structure or solid nests 
surrounded by clear space. Non-invasive implants are implants with or without 
stroma, which lack the above features. 
Benign bilateral borderline tumours occur in the child bearing age group hence 
surgery with conservation of as much as ovarian tissue with close clinical follow up 
until after childbearing is necessary. The overall prognosis remains good even in the 
presence of implants as they are usually behave as non invasive.14, 15 
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Malignant serous tumours: 
These are the most common malignant ovarian neoplasms accounting for 
approximately 40-50%16.These are usually large, often bilateral and exhibit a mixture 
of cystic papillary and solid growth patterns and the surface shows a growth on 
capsule due to capsular invasion; areas of haemorrhage and necrosis are also seen. 
Microscopically, well-differentiated type shows clearly formed papillary structures 
and with an immature connective tissue core. Psammoma bodies are very common in 
this type. A rare type of low grade serous carcinoma with a favourable prognosis is 
the psammoma carcinoma in which 75%of the tumour shows psammoma bodies. 
Moderately differentiated type shows finer and crowded papillae arranged in a lacy 
like pattern without fibro vascular core. Poorly differentiated serous carcinomas are 
the most common type which shows loss of micro papillary pattern of growth and the 
tumour cells are arranged in solid sheets. The cells at the margins are not palisaded 
and these tumours are associated with syncytial aggregates of tumour gaint cells. 
Immunohistochemistry plays a very important role in the diagnosis of these serous 
tumours. 
Although serous carcinomas are most often associated with papillae, other 
carcinomas  like transitional cell carcinoma, endometrioid carcinoma, clear cell 
carcinoma are usually papillary as well, thus entering the differential diagnosis. 
Endometrioid carcinomas have the villous papillae and associated with focal 
squamous differentiation which are not seen in serous carcinomas. In clear cell 
carcinoma, papillae are lined by hobnail or clear cells and typically have hyalinised 
cores. Transitional carcinomas show broad papillae lined by transitional cells forming 
undulating thick bands. Recommended strategies for serous carcinomas include 
presence of precursor lesions like borderline tumours, immunostaining of CK 7 
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positivity, CK 20 negativity, WT1 and P53 expression. Patients with poorly 
differentiated carcinomas present with advanced, inoperable stage with a poor 
prognosis5, 8. 
B) MUCINOUS TUMORS 
These tumours have an incidence of 14% of all ovarian tumours and 30.8% of 
all surface epithelial tumours with a prevalence of 75% being benign, 20% being 
borderline and 5% being invasive carcinomas. They occur in reproductive age group 
and are rare before puberty and after menopause. Usually, these tumours are 
unilateral, only5% of them shows bilaterality8, 16. 
Benign mucinous tumours: 
Macroscopically, most of these tumours are usually large with smooth outer 
surface, the cut surface shows multiloculated cysts containing watery or viscous 
mucoid material. Microscopically, these are classified as intestinal type and 
endocervical type depending on the lining epithelium of the cysts. In case of intestinal 
type, the cyst wall is lined by goblet cells and paneth cells showing picket fence 
appearance. Endocervical type shows ciliated columnar epithelial lining with 
abundant intracellular mucin resembling endocervical epithelium. 
Borderline mucinous cystadenoma: 
These are characterized by stratified cystic lining, not more than 3 layers and 
may form filiform intracystic papillae with at least minimal stromal support. Nuclear 
atypia, mitotic figures are seen. Stromal microinvasion is more common than serous 
tumours. The stromal microinvasion is defined as presence of isolated cells or 
clusters, each cluster composed of 5-10cells without stromal reaction15. 
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Malignant mucinous ovarian tumour (Mucinous adenocarcinoma): 
These are relatively uncommon tumours, seen between 40 to 80 years of age 
group. Macroscopically they are usually large tumours with smooth external surface, 
cut surface shows closely packed multilocular or thick walled unilocular cyst with an 
average diameter of 12 to 20cms. It also shows both solid and papillary cystic areas 
with areas of haemorrhage and necrosis. These are commonly unilateral, bilateral 
presentation always require exclusion of non-ovarian origin17. 
Microscopically, they show solid growth with loss of glandular architecture, 
the lining epithelium shows stratification of more than 4 layers and atypical changes 
with areas of necrosis and stromal invasion. Tumour invasion is ascertained by glands 
of varying sizes infiltrated in a haphazard pattern or confluent glandular growth with 
crowded glands that merges together or clusters of single cells with abundant 
eosinophilic cytoplasm surrounded by clear spaces5,8. Mucinous adenocarcinoma 
should be differentiated from metastatic colon adenocarcinoma. The latter shows 
bilaterality, surface involvement, nodular growth pattern, lymphovascular invasion, 
CK 20 positivity and CK 7 negativity17. 
Pseudomyxoma Peritonei: 
This entity is associated with mucinous ovarian neoplasm characterized by 
ovarian tumor with extensive mucinous ascites, cystic epithelial implants on 
peritoneal surface and produces adhesion. Most of the present studies confirmed that 
these are the metastases from appendiceal origin17. 
Mixed or collision tumour: 
They are defined by the exhibition of two or more of the epithelial elements 
present in various proportions. It may be a result of biphasic or multiphasic 
differentiation within the neoplastic tissue. It may also occur with germ cell or sex-
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cord stromal tumours. Most commonly, benign mucinous tumours are associated with 
mature cystic teratoma5. 
C) ENDOMETROID TUMORS: 
These tumours account for approximately 20-25% of all ovarian cancers 
excluding endometriosis, which is considered as non-neoplastic. Usually occur  in 
fifth decade. Most of the endometroid tumors are carcinomas. Less commonly benign 
forms and borderline cystadenofibroma are encountered. Atypical changes such as 
atypical hyperplasia within foci of endometriosis and hyperestrogenic state have 
increased malignant potential to become endometrioid carcinomas. Its coexistence 
with endometriosis suggests that the origin of tumour directly from ovarian coelomic 
epithelium18. It has a very good prognosis. 
Macroscopically, it presents as solid or cystic mass contains friable soft 
papillae admixed with hemorrhagic content partially filling the cystic lumen. 
Microscopically, they resemble that of ordinary type of well differentiated 
endometrial adenocarcinoma. This should be differentiated from metastases uterine 
endometrial carcinoma. Endometroid carcinoma of ovarian origin may have a foci of 
endometriosis, secretory change, expansile invasion, squamous metaplasia, and 
positivity of beta catenin and EMA 5,8,12. 
D) CLEAR CELL (MESONEPHROID) TUMORS: 
Clear cell carcinoma accounts for about 5% of all ovarian cancers. These 
tumours occur in 5th to 6th decade of life. Two third of ovarian tumours occurred in 
nulliparous women are associated with clear cell carcinomas5.These tumours 
frequently accompanied by pelvic and ovarian endometriosis18.Most are carcinomas, 
benign and borderline ovarian clear cell tumours are very rare. As benign and 
borderline tumours coexist with clear cell carcinoma, generous sampling is needed. 
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Macroscopically, they have thick walled unilocular cysts into which projects 
several fleshy nodules or presents with spongy cut surface. Microscopically the 
tumour cells are arranged in cystic tubular, papillary and solid sheets. Cores of 
papillae often exhibits prominent hyalinization lined by one or two layers of 
polygonal or hobnail or flattened cells. The cytoplasm is clear and often contains 
glycogen. Extra cellular mucin may be present. Nuclear atypia and mitotic activity is 
minimal. It should be differentiated from dysgerminoma by its polygonal shape, 
inconspicuous nucleoli, presence of luminal mucin and EMA positivity5,8,12.Metastatic 
renal cell carcinoma is almost indistinguishable, immunomarkers may be helpful in 
difficult cases, clear cell carcinoma shows CK7positivity and CD10 negativity, 
whereas the reverse findings are usually present in renal cell carcinoma17. 
E) BRENNER TUMOR: (TRANSITIONAL CELL TUMOR) 
These tumours constitute 1 to 2 % of all ovarian neoplasms. The mean age of 
incidence is 50 years. 5-7% of the tumours are bilateral16.These are hormonally active 
and produces hyperestrogenic state due to which uterine bleeding from endometrial 
hyperplasia occurs. Most authors currently favour an origin from surface ovarian 
epithelium or cyst derived from them through the process of metaplasia. They can be 
associated with transitional cell tumour of the bladder and mucinous cystadenoma. 
Most Brenner tumours are benign out of which 6% are bilateral. Borderline and 
malignant change is seen in more than 5% in clinically detectable cases. 
Macroscopically these are well circumscribed tumours, cut surface shows 
solid, firm nodule which is whitish or yellowish white in colour varying in size from 
less than 1cm to massive up to 22cmsto 30cms. Microscopically it consists of solid 
and cystic nests of epithelial cells resembling the urothelium surrounded by abundant  
dense fibroblastic stroma. The tumour cells are showing oval nuclei with a 
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longitudinal groove (coffee bean) and clear cytoplasm. Cystic change may be 
prominent, in some cases these are lined by mucinous epithelium. 
Borderline tumours show more prominent cystic component with papillary 
lining which consists of 25-50 layers, small spindle to oval shaped atypical cells 
without mitotic activity. Brenner tumour with irregular infiltrative stromal invasion 
called as malignant Brenner tumour5, 8, and 12. 
F) TRANSITIONAL CELL CARCINOMA: 
These tumours in ovary are broadly similar to transitional cell carcinoma of 
urinary tract in architectural arrangement and character. Mean age at presentation is 
around50 to 58 years. Macroscopically the tumours are usually cystic with a few solid 
areas and a mean diameter of 10 to 30cms.Cut surface shows the cysts with shaggy 
lining and contain friable polypoidal masses projecting from the walls and exude 
watery or mucinous fluid with areas of haemorrhage and necrosis. Microscopically 
the tumour is characterized by tufted papillary growth, slit like glands lined by 
transitional epithelium with more pleomorphism and mitotic activity without the 
Brenner component. It has got a good prognosis. It should be differentiated from 
metastatic tumours from urinary tract. Transitional carcinomas of urothelial origin 
show CK 20positivity which is negative in ovarian origin17. 
II. SEX CORD STROMAL TUMORS 
These comprise a heterogeneous group of neoplasms accounting for 5% of all 
ovarian neoplasms. It includes those tumours originating ultimately from the sex-cord, 
mesenchyme or both of the embryonic gonads. They can differentiate  either in the 
direction of testicular type of cells(Sertoli-Leydig cell tumours) or ovarian 
type(Granulosa cell tumours).They are functional tumours. Inhibin and Calretinin is a 
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sensitive and specific immunomarker of wide range of sex cord stromal tumors 
respectively and is of value in differential diagnosis of ovarian neoplasia5, 8, and 17.  
A) GRANULOSA STROMAL CELL TUMOR: 
These comprise of two groups: 
1) The granulosa cell tumour 
2) The thecoma fibroma group 
These are the ovarian neoplasms showing differentiation towards follicular 
granulosa cells. They account for 1-2% of all ovarian tumours and more than 70% of 
the sexcord stromal tumors. Majority occurs during childbearing age group, less than 
5% of the tumours appear before puberty; these are called as juvenile granulose 
celltumor19.  
a) Juvenile granulosa cell tumour: 
It is diagnosed in 80% of cases during the adolescent period presenting with 
precocious puberty. It can be associated with Ollier’s disease or Mafucci’s syndrome 
in a few cases20. 
Macroscopically, these present as large tumours with lobulated outer surface. 
Cut surface shows solid-cystic portions. The solid areas are yellow or tan in colour 
and soft in consistency. Microscopically they are showing diffuse cellular growth 
pattern punctuated by macro follicles and follicle like spaces of varying size and 
shapes. Neoplastic granulosa cells have abundant vacuolated cytoplasm and lack 
nuclear grooves admixed with numerous mitotic figures. Juvenile granulosa cell 
tumour shows very aggressive course and metastasize distantly when compared to 
adult granulosa cell tumour. 
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b) Adult granulosa cell tumour: 
These are diagnosed during childbearing age group and about 40% of them 
occur after menopause. Three fourths are associated with hyperestrogenism, which 
leads to abnormal uterine bleeding. The additional feature of these tumours lies in the 
fact that all are potentially malignant. But it is difficult from the histological 
evaluation of granulosa cell tumour to predict their prognostic significance. 
Macroscopically, these tumours vary in size with average of 12cms in 
diameter. Cut section shows solid and cystic areas, solid areas are yellow to greyish 
white in colour admixed with thin walled cysts filled with haemorrhagic fluid. 
Microscopically the growth pattern is highly variable. Micro follicular (Call Exner 
bodies) macro follicular, trabecular, insular, watered silk, solid and diffuse 
sarcomatoid patterns are seen. Previous studies showed that these patterns indicate 
about their prognosis like insular and trabecular pattern have good prognosis when 
compared to sarcomatoid pattern but the recent studies stated that microscopic 
patterns has no prognostic value, only tumour size and mitotic index have the 
prognostic significance.5, 21 An important diagnostic point of this tumour is the 
presence of folds or grooves in the nuclei resulting in coffee bean appearance. The 
important differential diagnosis is poorly differentiated carcinomas which shows 
bilateral involvement, often have spread beyond the ovary, and microscopically shows 
pleomorphic nuclei with extensive areas of necrosis. Immunohistochemical study of 
Inhibin positivity adjunct to morphology is helpful in diagnosis of granulosa stromal 
cell tumor17.  
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THECOMA- FIBROMA GROUP: 
a) Thecoma: 
They constitute 4% of all ovarian tumours. They occur at an average of 
53years and can produce estrogenic manifestation. 65%of patients are in the post 
menopausal age group.3Macroscopically; these are unilateral tumours, cut surface 
shows uniformly solid appearance with well-defined capsule, grey tan to golden 
yellow in colour, firm in consistency. Microscopically these are cellular tumours 
composed of fascicles of plump spindle shaped cells. The nuclei are fusiform and 
have finely dispersed chromatin with lightly eosinophilic or clear or vacuolated the 
cytoplasm. Special stains like Oil red O demonstrates intra cytoplasmic neutral fat, 
silver stains demonstrate reticulin around each tumour cells as opposed to granulosa 
cell tumour in which reticulin surrounds clusters of cells22. 
b) Fibroma: 
 Fibroma is a neoplasm of unspecialized ovarian stroma. One of the common 
ovarian tumour occurring invariably after puberty, which is often asymptomatic and 
discovered incidentally during surgery. Ovarian fibroma can be associated with 
ascites and right sided pleural effusion (Meigs syndrome).In Gorlin’s syndrome they 
present bilaterally23.Cellular fibromas may be associated with peritoneal implants. 
Macroscopically, these are unilateral tumours with an average of 6cms in 
diameter. Cut surface shows solid, lobulated appearance, white in colour, firm in 
consistency. Microscopically they show spindle shaped fibroblastic cells that grow in 
interlacing fascicles and whorls admixed with collagen. The tumour cells have bland 
fusiform nuclei with pointed ends. 
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C) STROMAL TUMOR WITH MINOR SEX CORD ELEMENTS:  
These are rare fibro thecomatous tumour containing scattered sex cord 
elements. This category is only appropriate when the sex-cord component is less than 
5% of the tumour. They occur in any age group and are usually hormonally active. 
Macroscopically, the tumour is solid and indistinguishable from thecoma or fibroma. 
Microscopically it shows the typical features of thecoma or fibroma in which sex cord 
structures are inter mingled with the fibro thecomatous cells, sex cord components 
vary in appearance between fully differentiated granulosa cells and indifferent tubular 
structures resembling sertoli cells5. 
D) SCLEROSING STROMAL TUMOR OF OVARY: 
These are uncommon benign neoplasms occurring in patients between 14-
29years of age. The tumour with rare exceptions is hormonally active. 
Macroscopically, these tumours arrange from 1 cm to 20cm in diameter, 
unilateral, cut surface shows solid, lobulated appearance, grey white in colour with 
occasional yellow foci, firm in consistency. On microscopically examination, they 
show pseudo lobular pattern of growth, composed of dual cell population:-collagen-
producing spindle cells, lipid containing round cells admixed with richly vascularised 
areas sharply demarcated from hypo cellular oedematous and sclerotic fibrous stroma. 
Reticulin stain shows the presence of reticulin fibres encircling individual tumor cells. 
The main differential diagnosis is massive oedema of ovary. In sclerosing stromal 
tumour, normal ovarian structure displaced by the neoplasm whereas in massive 
edema of ovary, the normal ovarian structure present within the oedematous areas5, 8. 
E) SERTOLI STROMAL CELL TUMOR: 
These are a group of tumours composed of varying proportion of Sertoli cells, 
Leydig cells and stromal elements which ranges from well to poorly differentiated. 
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Sertoli Leydig cell tumour: 
These tumours as the name indicates are composed of variable mixture of 
morphologically resembling male Sertoli cells and Leydig cells. These are uncommon 
tumours, comprise less than 0.1% of ovarian neoplasms3.Average age of presentation 
is25yearsandclinically presents with features of defeminisation and musculinisation. 
This tumour was previously called as Arrhenoblastoma or Androblastoma. 
Majority of the tumours are unilateral, firm, yellow to tan, solid masses with 
smooth external surface. The microscopic pattern is extremely variable. Based  on the 
amount of hollow tubules, variable types like well differentiated or intermediate or 
poorly differentiated arrhenoblastoma exists. About 20% of the tumours show 
heterologous elements, most commonly it shows mucinous epithelium of 
gastrointestinal tract, other components like skeletal muscle, cartilage and 
neuroendocrine cells have also been described. Immunohistochemically testosterone 
and estradiol are found in both Sertoli and Leydig cells24. The area of sertoli cell 
differentiation stain for Keratin and gonadal stromal component is positive for 
Inhibin17.The prognosis of Sertoli -Leydig cell tumour is good which correlates with 
the stage and degree of differentiation of the tumor8. 
F) SEX CORD TUMOR WITH ANNULAR TUBULES: 
It is a distinctive ovarian tumour, which occurs in two forms: as a multifocal 
bilateral tumours with the Peutz-Jeghers syndrome or as a solitary neoplasm without 
the syndrome.50% of patients present with hyperestrogenism. In several tumours the 
pattern merged with that of granulosa cell tumour admixed with elongated solid 
tubules resembling Sertoli cells. The characteristic microscopic feature is the presence 
of complex annular tubules filled with eosinophilic material, hyaline bodies 
associated with calcification. Syndrome associated tumours are typically showing 
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bilaterality, calcification and swollen appearance. The microscopic appearance is 
similar to that of gonadoblastoma from which it differ only by clinical and genetic 
background5, 8. 
G) GYNANDROBLASTOMA:  
Rarely mixtures of Granulosa cell tumours and Sertoli-Leydig cell tumours 
have been reported. So both androgenic and estrogenic manifestations produced by 
the same neoplasms. To make this diagnosis well differentiated elements of both the 
tumours should be present in equal amounts8, 12. 
H) LIPID CELL (LIPOID, STEROID CELL) TUMOR 
The exact origin of this tumour remains undecided. Therefore more recently 
the term steroid cell tumour has been proposed for the entire group, with added 
designation of Leydig cell type and cortical type whenever necessary. These tumours 
account for 0.5% of all ovarian neoplasms. It can occur at any age group and are 
associated with virilising syndrome and defeminisation. 
Macroscopically, these are usually unilateral, well circumscribed and are 
composed of  yellowish  nodules separated by fibrous septa. Microscopically these are 
characterized by masses of large polyhedral cells with abundant eosinophilic or 
vacuolated cytoplasm that shows positivity for fat stains. About 25% of tumours have 
tendency to develop malignancy. Malignant tumours tend to be larger with foci of 
necrosis and haemorrhage. Nuclear atypia and mitotic activity also seen5, 8. 
III.GERM CELL TUMORS: 
These tumours constitute approximately 20%of all ovarian neoplasms, out of 
which 3% are malignant tumors. Germ cell tumours are the commonest ovarian 
neoplasm in the first two decades of life constituting approximately two third of all 
ovarian tumors. The younger the age, the occurrence of malignancy will be high3, 25. 
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95% of the germ cell tumours are benign cystic teratoma25. The current pathogenetic 
theory suggests that, these tumours arising from the germ cell which has undergone 
defective meiotic division8.Most of the malignant ovarian tumours occur in pure form; 
approximately about 8% are composed of two or more subtypes called as malignant 
mixed germ cell tumour. 
A) DYSGERMINOMA: 
These are the most common germ cell tumours of the ovary accounting for 1% 
of all ovarian cancers and for 5-10% of ovarian cancers in first two decades of 
life.10% of the tumours are bilateral. It is also the most common malignant tumour, 
which occurs in patients with gonadal dysgenesis8, 25. Most commonly they present 
with abdominal mass and pain. Macroscopically, these are solid tumours with an 
average diameter of 15 cms and have a smooth bosselated external surface. Cut 
section shows a typically solid, lobulated, fleshy appearance; tan or white in colour 
and soft in consistency. Microscopically, the tumour cells are arranged in nests 
separated by fibrous septa with lymphocytic infiltration. Germinoma cells are round 
cells with abundant clear to eosinophilic cytoplasm, prominent cytoplasmic 
membranes, round vesicular nucleus and central prominent nucleoli. Periodic Acid 
Schiff stain helps in demonstrating the presence of intra cytoplasmic glycogen. 
Anaplastic dysgerminoma: This is a variant of dysgerminoma where the 
tumour cells are arranged in pseudo glandular or tubular pattern with a high mitotic 
rate, accompanied high nuclear atypia which simulates the embryonal carcinoma. 
Immunostainig of these tumours show a strong positivity usually a membranous 
pattern for Placental alkaline phosphatase and CD117.Especially CD117 is useful in 
differentiating the two, because embryonal carcinoma is CD117 negative.8, 26 
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B) YOLK SAC TUMOR (ENDODERMAL SINUS TUMOR): 
They are almost as common as dysgerminoma in younger women, constituting 
20% of primitive germ cell tumour. Most of the patients present with abdominal pain, 
distension or abdominal mass. 
Macroscopically, these tumours tend to be unilateral and large with an average 
diameter of 16 cms. Cut section shows a soft, friable, and yellow to greyish white 
tissue often containing cysts with extensive areas of haemorrhage and necrosis. 
Microscopically these tumours have a more than one pattern, which could be reticular, 
solid, festoon, pseudo papillary, and hepatoid or polyvesicular vitelline pattern. 
Schiller Duval bodies are the characteristic feature of this tumour. They consist of 
papillae lined by tumour cells that project into dilated cystic spaces, resulting in 
somewhat glomeruloid appearance. Eosinophilic hyaline globules which are PAS 
positive diastase resistant are seen in yolk sac tumors5, 8.Small enteric glands are lined 
by columnar or goblet cells or malignant embryonal stroma containing spindle or 
satellite cells are present in yolk sac tumors. They consistently produce alpha 
fetoprotein which can be demonstrated in tissue sections by immunohistochemistry or 
in serum. They also immunoreactive for Cytokeratin, Alpha1 antitrypsin but not with 
EMA 17. 
Clear cell carcinoma is the tumour more often confused with Yolk sac tumor. 
The nuclei in Yolk sac tumours are almost always more primitive in appearance and 
the papillae are simple containing a single central vessel and lacking the hyalinised 
core in contrast to clear cell carcinomas. Immunoprofile of CK7 positivity, EMA 
positivity and Alpha fetoprotein negativity strongly favours the diagnosis of clear cell 
carcinoma27. 
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C) EMBRYONAL CARCINOMA: 
Embryonal carcinoma is very rare accounting for at most 3% of primitive 
ovarian germ cell tumors. These tumours occur in younger age group with a median 
age of 15 years presenting  with precocious puberty, vaginal bleeding, hirsutism and 
amenorrhea. Macroscopically, it shows smooth and glistening external surface with a 
mean diameter of 17cms.Cut surfaces are predominantly solid and variegated with 
areas of haemorrhage and necrosis. Microscopically it shows solid sheets and nests of 
tumour cells, which are large primitive cells with occasional papillae and abortive 
glandular structures. Isolated syncytiotrophoblastic gaint cells are always present. 
Serum alpha-fetoprotein is often elevated whereas chorionic gonodotropin are 
invariably high to a level that results in consistently positive pregnancy tests5, 
8,12.These tumours may be confused with a poorly differentiated adenocarcinoma or 
undifferentiated carcinoma, however such tumours typically occur in the late 
reproductive or postmenopausal age group, rarely elaborate alpha fetoprotein and they 
lack trophoblastic differentiation27. 
D) POLYEMBRYOMAS:  
Embryonal carcinomas consists of numerous embryonal bodies are called as 
Polyembryomas. These structures are highly organised, showing an embryonic disc, 
yolk sac and amniotic cavities5. 
E) CHORIOCARCINOMA: 
Primary ovarian choriocarcinomas account for less than 1% of primitive 
ovarian germ cell tumours. Most Choriocarcinomas are as a result of metastasis from 
uterine tumors. So some authors using the strict criteria would only accept as non-
gestational Choriocarcinoma those cases occurring before puberty, because ovarian 
gestational choriocarcinoma have a better prognosis than non-gestational 
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choriocarcinoma5.Pure choriocarcinomas are typically solid, haemorrhagic and friable 
masses. Microscopically they show typical biphasic plexiform pattern consisting of 
admixture of syncytial and cytotrophoblastic elements in a necrotic and hemorrhagic 
background. 
Immunohistochemical reactivity for HCG (human chorionic gonodotropin) is 
the rule in addition keratin7 is said to represent a marker for subtype of trophoblastic 
cells. Typical microscopic picture with immunomarkers used to distinguishes from 
exceptionally rare ovarian carcinoma of surface epithelial origin exhibiting 
choriocarcinomatous differentiation27. 
F) TERATOMA: 
Teratomas are composed of tissues representing at least two, but usually all 
three embryonic layers. They are divided into three types- Immature teratoma, mature 
teratoma and Monodermal teratoma. 
1) IMMMATURE TERATOMA: 
 It is a malignant teratoma in which the malignant elements have an embryonal 
appearance. These are  the third most common primitive germ cell tumour accounting 
for almost 20% of all cases and 1% of ovarian cancers in general25.It occurs in 
children and young adult with an average age of presentation is 20 years. These are 
unilateral tumours with average diameter of 17 to 18 cms. Cut section shows partly 
solid and cystic areas, solid areas are typically soft, fleshy with focal haemorrhage 
and necrosis.  
Microscopically it shows the tissues derived from all the three germ layers, 
growing as disorganized mixture of mature and immature elements. Neuroepithelial 
tubules and rosettes are easily recognized elements that are indicative of immaturity in 
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teratoma. Immature cartilage, fat, endodermal glands, and liver tissue are also 
recognized.   
               Table 1 Grading of immature teratoma 
Grade  Immature tissue Amount of Neuro epithelium 
1 + Rare , not > 1 LPF / slide 
2 ++ Common, not > 3 /LPF / slide 
3 +++ Prominent ,>4/LPF/slide 
 
Immature teratoma must be graded, since the prognosis depends on the grade 
as well as the stage. The most widely used grading system (Norris system). Norris et 
al stratifies immature teratoma into three grades based on the amount of immature 
neuroepithelial elements28 (Table1) 
Grade 3 tumours can be associated with undifferentiated cells with occasional 
differentiations into glial masses, ependymal, neuroblastic and medulloepithelioma 
like arrangements5.Serum Alfa fetoprotein is a useful marker in this tumour as some 
patients have shown increased levels. Immature teratoma should be differentiated 
from carcinosarcoma with heterologous elements; the former shows neuroepithelial 
elements and occur in younger age group. 
2) MATURE CYSTIC TERATOMA: 
The most common benign tumour in Western world is benign mature cystic 
teratoma or dermoid cyst, account for approximately 25% of all ovarian tumors, 30% 
of benign ovarian tumors; 85-90% of germ cell tumor.85% of patients is between 20 
to 50 years of age. It is unilateral in 88%of cases.24 
Macroscopically, they are multiloculated cysts, with a greasy content largely 
composed of keratin, sebum hair and teeth. Sometimes the tumour contains 
imperfectly formed mandible or even partial human body like 
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configuration(homunculus) called as fetiform teratoma. Single or several rounded, 
polypoidal masses designate Rokitansky protuberances and composed of variety of 
tissue types. If solid areas are present it should be sampled carefully to rule out 
immature teratoma. Microscopically the tumour contains a variable admixture of 
ectodermal, mesodermal, and endodermal elements such as hair follicles, epithelium, 
salivary gland, thyroid, and respiratory tract epithelium. Rarely a benign cystic 
teratoma is associated with peritoneal glial implants or peritoneal melanosis. Mature 
cystic teratoma can coexist with mucinous cystadenoma, Brenner tumour and 
fibrothecoma. Secondary malignancy can occur in benign cystic teratoma; this 
complication is common in postmenopausal women. Secondary neoplasms are usually 
unilateral, but contralateral ovary may contain a benign cystic teratoma. A variety of 
benign and malignant tumours can occur; benign tumours include cutaneous adnexal 
tumour and benign salivary gland tumours, whereas the most common malignant 
tumour is squamous cell carcinoma29. 
3) MONODERMAL TERATOMA: 
This term applies only to the unilateral differentiation of tissues derived from 
one of the germ cell layers. Struma ovary is the most common tumour in this group; 
carcinoid tumour and neuroectodermal tumours are next commonly encountered 
tumours. 
a) STRUMA OVARII: 
Thyroid tissue is the unique and predominant component in this teratoma. 
Most are benign and malignant Struma ovary is very rare. The features that define 
malignancy include invasion of one cell into another or papillary pattern with typical 
nuclear characteristics. Macroscopically, these tumours are less than 10cm in diameter 
Cut section shows solid, tan, or brown in colour with a glistening appearance. 
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Microscopy shows the tumour consists of thyroid follicles filled with eosinophilic 
colloid and lined by columnar or cuboidal bland cells5, 8. 
b) CARCINOID TUMOR: 
These  neuroendocrine tumour occurs in older age group, presenting with 
menstrual irregularities and pelvic and abdominal pain. Macroscopically, the primary 
carcinoids are unilateral, cut surface shows solid tumour, tan or yellow in colour. 
Microscopical examination shows the tumour cells composed of uniform round to 
cuboidal cells arranged in trabecular pattern that have a round nucleus with coarse salt 
and pepper chromatin. The ovary is the most common site of metastasis from 
carcinoid of gastrointestinal tract (usually from small intestine or 
appendix)27.Evidence favouring for metastatic carcinoid includes bilaterality, intra 
ovarian growth in the form of several nodules, probable presence of a carcinoid in the 
other sites. Neuroendocrine immunomarkers like Serotonin, Chromogranin shows 
positivity5,8. 
G) MALIGNANT MIXED GERM CELL TUMOR: 
These comprise 5 to 20 % of all malignant germ cell tumors3. These contain a 
mixture of malignant germ cell elements, commonly shows a combination of 
dysgerminoma and yolk sac tumour, followed by immature teratoma, Embryonal 
carcinoma and Choriocarcinoma. They occur exclusively in children and young 
women with an average age presentation are 16 years. Tumours composed of Yolk 
sac tumour, or choriocarcinoma, or highly immature teratoma have poor prognosis, 
than when dysgerminomas or more mature teratomas predominate.30 
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H).MIXED GERM CELL-SEXCORD-STROMAL TUMORS: 
A) GONADOBLASTOMA: 
These are tumours composed of a combination of germ cells and sex cord 
stromal cells .It is also known as dysgenetic gonadoma. As per the name, these occur 
in sexually abnormal individuals affected by gonadal dysgenesis; commonly 
associated with XY gonadal dysgenesis but not in XX gonadal dysgenesis.30% of the 
tumours are bilateral and usually are small; become apparent only by microscopic 
examination. Microscopically these are characterized by admixture of primitive germ 
cells resembling those of dysgerminoma with sex cord stromal cells resembling that 
of immature sertoli and granulosa cells. Hyalinization and calcification are common. 
Gonadoblastoma can be confused with sex cord tumours with annular tubules but the 
latter lacks the germ cell component5, 8,12. 
IV) TUMORS OF THE RETE OVARII:  
These are relatively uncommon tumours, which includes adenoma, 
cystadenoma and carcinoma. 
V) TUMORS OF UNCERTAIN ORIGIN 
A) SMALL CELL CARCINOMA: 
There are two types of small cell carcinoma designated as hypercalcemic and 
pulmonary type respectively. 
Hypercalcemic type: It is by far the most common form of undifferentiated 
carcinoma, which occurs in young females and is nearly always bilateral. These 
tumours are associated with hypercalcemia in two third of cases which disappear 
following removal of tumor. Macroscopically these tumours are large, solid with 
areas of haemorrhage and necrosis. On microscopical examination it shows diffuse 
population of small, closely packed cells of scanty cytoplasm, small hyperchromatic 
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nuclei containing prominent nucleoli with numerous mitotic figures. Cytoplasmic 
hyaline globules are seen. The prognosis is very poor because of frequent extra 
ovarian spread. 
Pulmonary type: This tumour resembles in all regards with lung tumour. It 
may be pure and associated with endometrial carcinoma. Immunohistochemistry 
reveals these tumours are positive for keratin, EMA, NSE and rarely for 
chromogranin17. 
B) TUMOR OF PROBABLY WOLFFIAN ORIGIN:  
This tumour is now renamed as Wolffian adnexal tumour; because the exact 
histogenesis is still arguable whether it could be due to mesonephric origin or sex cord 
stromal origin or it has been regarded as of uncertain origin. These are benign 
tumours which are grossly either solid or cystic, grey white or yellow in colour. 
Microscopically, these tumour epithelial cells grow in the form of cystic structures, 
solid or hollow tubules and diffuse sheets. They show negative staining for mucin. 
Immunohistochemistry shows positivity for keratin (CK7 but not CK 20) Calretenin 
and Vimentin. In a few cases Estrogen, Progesterone and Inhibin positivity is also 
recorded17. 
VI. UNCLASSIFIED TUMORS 
SARCOMAS: 
The primary sarcoma of ovary is extremely rare. Some of the soft tissue 
tumours, which occur in ovary, are fibrosarcoma, endometrial sarcoma, 
leiomyosarcoma, chondrosarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma 
and peripheral neuroectodermal tumour. 
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Fibrosarcoma:  
These are rare ovarian tumours but one of the most common ovarian 
neoplasms. Commonly occur in postmenopausal age group. Macroscopically they 
show solid fleshy cut surface with areas of haemorrhage and necrosis. 
Microscopically these tumours show spindle shaped cells arranged in herringbone 
pattern with nuclear atypia admixed with numerous mitotic figures12. 
VII. METASTATIC TUMORS (SECONDARY TUMORS) 
The ovary is a common frequent site of metastasis from stomach, large bowel, 
appendix, breast, uterus, lung and skin. Features of metastasis include bilaterality, 
surface involvement by tumour cells, infiltrative nodular pattern of growth, ovarian 
hilar involvement, single cell invasion, presence of signet ring cells and dirty 
necrosis.31 
Macroscopically, they vary in appearance; ovary is completely replaced by 
solid white or tan metastatic tumour or grows as large unilocular or multilocular 
cystic tumour with solid areas. Bilaterality and multiple serosal implants on ovary are 
particularly suggestive of metastasis. 
Microscopically there is a multifocal involvement of the ovary with implants 
on the surface. The tumour cells may diffusely infiltrate the parenchyma or grow in 
discrete nodules. The diagnosis of metastasis is difficult when the secondary disease 
simulates the primary tumour. Immunohistochemical stains like CK 7 and CK 20 are 
helpful in establishing the diagnosis, primary ovarian tumours shows CK 7 positivity 
and CK 20 negativity17. 
KRUKENBERG TUMOR: 
It is a form of metastatic cancer in which signet-ring type cell grows in 
abundant hyper cellular stroma. The stomach is the usual primary site for this tumour. 
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It shows high incidence in females and Japanese population. Macroscopically the 
ovaries are usually retaining their shape but they are symmetrically or asymmetrically 
enlarged. Cut section shows homogenous appearance with firm, yellowish white 
areas, soft in consistency. Microscopically the tumour cells grow in as isolated single 
cells, form nests, cords or tubules. The tumour cells contain round cytoplasmic 
vacuoles that compress and flatten the hyper chromatic nucleus against the one cell 
border resulting in signet- ring appearance. The stroma shows pools of mucin. Special 
stains for mucin (PAS, Alcian blue) andimmunostains of epithelial markers are 
helpful in diagnosis. However according to Novak and Gray criteria, it is diagnosed if 
presence of intracellular mucin within the neoplastic signet ring cells and diffuse 
sarcomatoid proliferation of ovarian stroma. Prognosis of Krukenberg tumour is still 
very poor but there are no established criteria for it32. 
PROGNOSIS OF OVARIAN TUMORS: 
The prognosis of ovarian tumours depends on various factors. The important 
factors influencing the ovarian cancer prognosis are histological type, stage of ovarian 
cancer, molecular abnormality, woman’s age and general health-whether the cancer 
has just been diagnosed or has recurred. TNM and FIGO Classification of staging is 
used in ovarian cancers 8, 33.  
NON NEOPLASTIC LESIONS 
Non neoplastic lesions may form pelvic masses, associated with hormonal 
manifestations, mostly simulating ovarian neoplasm, so recognizing them is important 
from the view point of therapy and prognosis. 
EPITHELIAL INCLUSION CYST: 
These arise from cortical invagination of surface epithelium that has lost their 
connection with the surface. Those that develop in fetal life is called fetal inclusion 
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cyst lined by primitive celomic epithelium and those that develop as aging process, 
lined by celomic epithelium are named as acquired inclusion cyst. They can measure 
up to 1cm in diameter. Most are incidental findings in the form of single to multiple 
cysts scattered throughout the superficial cortex. The infrequent finding of dysplastic 
epithelium lining the cyst support the hypothesis that they give rise to surface 
epithelial carcinoma. 
In few instances hydropic change of the lining epithelial cells can mimic that 
of signet ring cell carcinoma, the latter shows deep invasiveness, presence of 
intracellular mucin and can be associated with necrosis27. 
FOLLICULAR CYST: 
They develop from distension of atretic or developing follicle and do not 
exceed 10cm in diameter and when less than 2.5cm are called as cystic follicle. It may 
occur in any age, infancy to menopause. In women with reproductive age group, it is 
associated with menstrual irregularities, or may rupture causing acute abdominal pain 
with haemoperitoneum. 
Macroscopically, they are unilocular, smooth surfaced, thin walled cysts 
containing serous or serosanguinous fluid. Microscopically, they are lined by inner 
granulosa cells and outer theca interna cells with luteinisation in either layer of cells. 
Foci of luteinised cells show marked pleomorphism in pregnancy and puerperium. 
This should be differentiated from cystic granulosa cell tumour which is rarely 
uniformly luteinised with nuclear grooves and never containing bizarre nuclei. 5, 27 
CORPUS LUTEAL CYST: 
They are single and usually less than 6cm in diameter. They usually develop at 
the end of menstrual cycle or may occur in pregnancy. Macroscopically, the cyst wall 
is yellow or convoluted, often containing bloody fluid. Microscopically, the cyst wall 
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is composed of thick convoluted layer of large luteinised granulosa cells interrupted 
externally by wedges of much smaller theca lutein cells. These architectural and 
cytological features are important in differentiating from luteinised follicular cyst.5, 27 
POLYCYSTIC OVARIAN DISEASE, STROMAL HYPERTHECOSIS, 
STROMAL HYPERPLASIA: 
These disorders may be associated with androgenic or estrogenic 
manifestations. 
Polycystic ovarian disease or Stein Levanthal Syndrome: 
PCOD has been estimated in about 3.5-7% of female population. Clinical 
manifestations are obesity, hirsuitism, menstrual irregularities with increased serum 
luteinising hormone and decreased follicle stimulating hormone. Macroscopically, 
they are opaque with thickened capsule; cut section revealed equally sized multiple 
cysts, situated superficially beneath the capsule with central homogenous stroma. On 
microscopic examination, the outer cortex is hypo cellular, containing cysts lined by 
hyperplasic, enlarged, lipid-laden theca interna cells. Granulosa cells are less 
conspicuous and are not luteinised. It is managed medically by regulation of 
menstrual cycle & ovulation induction5, 8. 
Stromal hyperplasia and stromal hyperthecosis: 
They are most commonly present in postmenopausal women at 6th to 
7thdecade.It may be associated with estrogenic or androgenic effects, obesity, 
hypertension. Gross features are bilateral ovarian enlargement, each ovary measures 
approximately 8cm in diameter simulating ovarian tumour. Cut surface shows 
homogenous appearance, white to yellow in colour, firm in consistency. 
Microscopically they show diffuse or nodular proliferation of plump ovarian cortical 
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cells encroaching on the medulla. It may be associated with endometrial hyperplasia,  
and adenocarcinoma5,8. 
ENDOMETRIOTIC CYST: 
Ovary is the most common site of endometriosis34.Pain associated with 
menstrual cycle is the most common symptom. Macroscopically, they show small, 
slightly raised blueberry spots on the ovarian surface, often accompanied by fibrous 
adhesions and in extensive involvement the entire ovary may be converted into 
chocolate cyst. On microscopical examination ovary shows endometrial glands and 
stroma associated with fresh or old haemorrhages. It may be the site of reactive 
atypia, hyperplasia, metaplasia or malignancy. Endometrioid adenocarcinoma, clear 
cell carcinoma are thought to arise from foci of endometriosis18. 
MASSIVE EDEMA OF OVARY: 
Accumulation of edema fluid within the ovary has been designated as massive 
ovarian edema. These are common in younger age and unilateral in 90% of the cases. 
Macroscopically, they present as enlarged, soft, fluctuant ovary with smooth outer 
surface. Sectioning shows homogenous, pale appearance, exuding a watery fluid. 
Microscopically it shows abundant pale staining fluid that surrounds the follicle and 
typically spares the superficial cortex. It should be differentiated from ovarian 
neoplasm with oedematous and myxoid appearance, such as sclerosing stromal 
tumour, Krukenberg tumour and edematous fibroma27. 
GRANULOSA CELL AND SERTOLI CELL PROLIFERATIONS: 
Focal proliferations of granulosa cells commonly occur during pregnancy. 
They typically develop in atretic follicles, microscopy reveals small aggregates of 
granulosa cells that shows trabecular, diffuse, insula rpattern. They are differentiated 
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from small granulosa cell tumours by their microscopic size, multifocality, 
confinement to atretic follicle and common occurrence during pregnancy35. 
PREGNANCY LUTEOMA: 
It is a tumour derived from luteinised theca and stromal cells. Grossly they 
appear as bilateral, multiple, solid nodules with soft, fleshy, yellowish brown cut 
surface. Microscopic examination shows sharply circumscribed nodules of polygonal 
cells with granular, eosinophilic cytoplasm. This tumour should be differentiated from 
sex cord stromal tumours, where the latter is almost always unilateral, solitary and 
have a denser reticulin pattern27, 35. 
INFLAMMATORY LESIONS OF THE OVARY: 
Pelvic inflammatory disease of bacterial origin accounts for most common 
infection in developed countries. Ovarian involvement stems from salpingitis and 
typically takes in the form of bilateral tubo ovarian abscess and healed abscess is 
converted into a tub ovarian cyst, that may mimic ovarian cystic neoplasm during 
surgery. So careful microscopical examination of inflamed tubal plicae gives a clue to 
the diagnosis. 
Ovarian involvement is present in only 10% of cases of pelvic 
tuberculosis36.On gross examination the ovaries typically have tubal-ampullary 
adhesions. Microscopically they show caseating granulomas confined to the ovarian 
cortex. 
Other infectious agents producing granulomatous oophoritis are actinomyces 
schistosomiasis, whereas non-infectious granulomatous causes are sarcoidosis, 
foreign body granuloma and Crohn’s disease.37 
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MATERIALS AND METHODS 
Our study is a retrospective study carried out in the Department of Pathology, 
Tirunelveli Medical College, Tirunelveli  from Januaruy 2008 to December 2010.This 
study was undertaken to find out  the incidence and analyse the  histomorphological 
patterns of ovarian lesions in and around Tirunelveli. 
Clinical details of the patients including the age, parity, hormonal status  and 
examination findings were recorded from the case sheets available in the Medical 
Records Department . The necessary laboratory parameters including serum markers 
like CA-125, Alpha Feto Protein, Human Chorionic Gonadotropin if done were noted. 
The reports of all the radiological investigations viz.Ultra sonography,  Computerised 
Tomography, MRI  and FNAC report were recorded. The cases with diagnostic 
difficulties were discussed with the gynaecologists.  
Gross and microscopic features of all the cases were noted from the records 
available in the Department. Slides and blocks were retrieved from the store, further 
sections were taken from the block and stained with hematoxylin and Eosin and the 
findings were noted. Special stains like PAS, Reticulin, Alcian blue were performed 
as per standard staining protocol (Appendix II). Immunohistochemical markers 
including Cytokeratin, Epithelial membrane antigen, Alpha Inhibin and Alpha feto 
protein were performed in equivocal cases. Finally histopathological findings of all 
the cases were analysed and the tumors were classified according to recent WHO 
classification.12  
INCLUSION CRITERIA : 
1. All patients who are preoperatively diagnosed as having ovarian lesions and 
operated in Tirunelveli Medical College. 
2. Patients of all ages. 
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3. Both neoplastic and non-neoplastic ovarian lesions were included in this 
study. 
EXCLUSION CRITERIA: 
Incidentally found ovarian lesions in patients operated for other 
gynaecological problems were excluded from this study. 
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OBSERVATION AND RESULTS 
This retrospective study included the period of 3 years from January 2008 to  
December 2010, in Department of Pathology, Tirunelveli Medical college.203 ovarian 
lesions were analysed, of these 165 cases were neoplastic lesions,38 cases were non 
neoplastic lesions. 
Clinical features, gross and microscopic features were recorded in a proforma 
(Appendix I). These details were then transcribed into a master sheet and were 
analysed. 
INCIDENCE OF OVARIAN CANCERS: 
TABLE 2 Incidence of ovarian cancers among gynaecological cancers 
S.NO Type of Cancers No of cases Percentage (%) 
1 Gynaecological cancers 439 100 
2 Ovarian cancers 36 8.2 
 
As shown in Table 2, during the period of Jan 2008 –Dec 2010, 439 
gynaecological cancers were reported, out of which 36 cases were ovarian cancers, 
accounting for 8.2% incidence of total gynaecological cancers. (Chart 1) 
Chart 1 Incidence of ovarian cancers among gynaecological cancers 
100
8.2
Incidence
Gynaecological cancers
Ovarian cancers
 
41 
 
DISTRIBUTION OF NEOPLASTIC AND NON NEOPLASTIC OVARIAN 
LESIONS  
TABLE 3 Distribution of neoplastic and non-neoplastic lesions. 
Non neoplastic lesions Neoplastic lesions Total 
No of cases Percentage(%) No of cases Percentage(%)   
38 18.71 165 81.28 203(100%) 
 
As shown in Table 3, among 203 ovarian lesions,165 cases were neoplastic 
lesions, accounting for 81.28%, 38 cases were non neoplastic accounting for 18.71%. 
Increased incidence of neoplastic lesions was observed in our study. 
 
DISTRIBUTION OF BENIGN, BORDERLINE AND MALIGNANT LESIONS: 
TABLE 4 Distribution of benign, borderline and malignant ovarian lesions 
Benign tumours Borderline tumours Malignant tumours 
Total(%) 
No of cases (%) No of cases (%) No of cases (%) 
127 76.96 2 1.21 36 21.81 165(100%) 
 
As shown in Table: 4, among 165 neoplastic lesions, 127(76.96%) cases were 
benign, 36(21.81%) cases were malignant, and 2 (0.01%) cases were borderline 
tumours. Increased incidence of benign tumours were observed in this study.(Chart 2) 
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AGE DISTRIBUTION AMONG NEOPLASTIC LESIONS: 
TABLE 5 Distribution of benign, borderline and malignant ovarian neoplasm in 
different age groups 
 
Peak incidence of benign ovarian tumours were in the age group of 20-39years 
(56cases,44.09% of all benign ovarian neoplasms).Peak incidence of malignant 
ovarian neoplasm was seen in the age group of 40-59years (16 cases,44.44% of all 
malignant neoplasms).The youngest patient was 15 year old, whereas the oldest 
patient was 77 year old.(Table 5)(Chart 3) 
 
 
 
 
 
 
 
 
S.No 
Age 
group 
Benign tumours Borderline tumours Malignant tumours 
Total 
(%) 
 Years No of cases % No of cases % No of cases %  
1 <19 3 2.36 0 0 2 5.55 5(3.03) 
2 20-39 56 44.09 1 50 6 16.66 63(38.18) 
3 40-59 54 42.51 1 50 16 44.44 71(43.03) 
4 >60 14 11.02 0 0 12 33.33 26(15.75) 
 Total 127 100 2 100 36 100 165(100) 
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Chart 2 Distribution of Benign. Borderline and Malignant neoplasms 
 
 
Chart 3 Distribution of benign, borderline and malignant ovarian neoplasm in 
different age groups 
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CLINICAL PRESENTATION OF NEOPLASTIC LESIONS: 
 
TABLE 6Mode of presentation of neoplastic lesions 
S.No Clinical presentation No of cases % 
1 Abdominal pain 52 31.51 
2 Abdominal mass 23 13.93 
3 Bleeding per vagina 5 3.03 
4 Abdominal pain with mass 78 47.27 
5 Abdominal pain with bleeding per vagina 7 4.24 
 Total 165 100 
 
Among the neoplastic lesions almost half of the cases were associated with 
combination of symptoms, commonly presented with abdominal pain and abdominal 
mass (78cases,47.27%). Abdominal pain was the single most presenting symptom 
followed by abdominal mass (52 cases, 41.51%)  (Table 6). 
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LATERALITY OF THE NEOPLASTIC LESIONS: 
TABLE 7 Laterality of Benign, Borderline and Malignant tumours. 
 
S.No Tumour type 
Laterality Total 
U/L 
No of cases 
% 
B/L 
No of cases 
% No of cases 
1 Benign 123 97.63 4 2.36 127 
2 Borderline 2 1.21 - - 2 
3 Malignant 22 61.11 14 38.88 36 
 Total 147 18 165 
 
 
In our study, 97.63% of the benign tumours were unilateral whereas 38.88% 
of the malignant tumours were bilateral. Bilaterality was more common in malignant 
tumours.(Table 7 ) 
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GROSS FEATURES OF NEOPLASTIC LESIONS: 
1) TUMOUR SIZE: 
TABLE 8 Variation in size among neoplastic lesions 
S.No Size (cms) No of cases Percentage (%) 
1 0-10 95 57.57 
2 11-19 53 32.12 
3 20-29 14 08.48 
4 30 and above 3 01.81 
 Total 165 100 
 
Among the neoplastic lesions majority of the cases were less than 10cms (95 
cases; 57.57%). (Table: 9). The smallest tumour had a size of 5x3x3cms, diagnosed as 
serous cystadenofibroma. Largest tumour measured 35x30x10cms which was 
diagnosed as mucinous cystadenoma. (Table 8) 
2) CONSISTENCY: 
TABLE 9 Gross morphology of the ovarian lesions 
S.No Gross morphology 
No of cases (%) 
Total(%) 
Benign Malignant Borderline 
1 Cystic 109(99.09%) 0 1(0.9%) 110(66.6) 
2 Solid 6(30%) 14(70%) 0 20(12.12) 
3 Solid and cystic 11(31.42%) 23(65.71%) 1(2.8%) 35(21.21) 
 
Present study showed that 99% of the benign tumours were cystic whereas 
70% of the malignant tumours were solid in consistency. 65.7% of the malignant 
tumours had solid-cystic cut surface. (Table 9) 
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DISTRIBUTION OF OVARIAN NEOPLASMS ACCORDING TO THE 
HISTOLOGICAL TYPE: 
Table 10 Distribution of ovarian neoplasms based on histological types 
S.No Types No of cases % 
1 Surface epithelial tumours 128 77.57 
2 Germ cell tumours 27 16.36 
3 Sex cord stromal tumours 7 4.24 
4 Miscellaneous 3 1.8 
 Total  165 100 
 
Table 10 shows among 165 neoplasms, surface epithelial tumours were the 
commonest neoplasm, comprised of 77.57% of the total neoplasms. Germ cell 
tumours were seen in 27 cases (16.36%). Sex cord stromal tumours were seen only 
4.24% of total neoplasms. (Chart 4) 
DISTRIBUTION OF SURFACE EPITHELIAL TUMOURS: 
TABLE 11 Distribution of surface epithelial tumours 
Serous tumours 
No of cases(%) 
Mucinous tumours 
No of cases (%) 
Benign Borderline Malignant Benign Borderline Malignant 
65(76.47) 2(2.35) 18(21.17) 34(85) 0 6(15) 
Total-85(100) Total-40(100) 
 
As shown in Table 11.Serous tumours were more common (66.4%) among 
surface epithelial tumours, followed by Mucinous tumours(31.25%).Each case of 
Endometrioid carcinoma, Clear cell carcinoma, Brenner tumour(0.78%) was reported. 
(Chart 5) 
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Chart 4 Distribution of ovarian neoplasms based on histological types 
 
 
 
Chart 5 Distribution of surface epithelial tumours 
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DISTRIBUTION OF BENIGN OVARIAN NEOPLASMS: 
TABLE 12 Distribution of benign ovarian neoplasms 
S.No Types No of cases % 
1 Serous cystadenoma 60 46.51 
2 Serous cystadenofibroma 5 3.87 
3 Mucinous cystadenoma 34 26.35 
4 Brenner tumour 1 0.78 
5 Dermoid cyst 22 17.32 
6 Fibroma 2 1.57 
7 Fibrothecoma 3 2.36 
 Total 129 100 
 
Present study showed that Serous cystadenoma was the commonest benign 
ovarian tumour seen in 60 cases (46.51%).Second most common tumour was 
mucinous cystadenoma (34cases,26.35%), followed by dermoid cyst (22 cases, 
17.32%) (Table12)(Chart 6) 
Chart 6 Distribution of benign ovarian neoplasms 
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DISTRIBUTION OF MALIGNANT OVARIAN TUMORS 
                 TABLE 13 Distribution of Malignant ovarian tumours 
S.No Histological types No of cases Percentage (%) 
1 Serous cystadenocarcinoma 18 50 
2 Mucinous cystadenocarcinoma 6 16.66 
3 Endometrioid carcinoma 1 2.77 
4 Clear cell adeno carcinoma 1 2.77 
5 Yolk sac tumour 1 2.77 
6 Malignant mixed germ cell tumour 4 11.11 
7 Granulosa cell tumour 2 5.55 
8 Miscellaneous  3 8.33 
 Total  36 100 
 
As shown in Table 13, serous cystadenocarcinomas were the commonest 
malignant ovarian tumour (18 cases, 50%).Mucinous cystadenocarcinomas was the 
second most common tumour (6 cases, 16.66%). (Chart 7) 
Chart 7 Distribution of malignant ovarian tumours 
50
16.66
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Yolksac tumor
Granulosa cell tumor
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DISTRIBUTION OF OVARIAN NEOPLASMS AMONG DIFFERENT AGE 
GROUPS 
 
Table 14 Distribution of ovarian neoplasms among different age groups 
 
 
Surface epithelial tumours were common in the age group between 40-
59years.Germ cell tumours were common in younger age group (10-40years) (Table 
14) 
S.No 
Age 
group(years) 
Surface epithelial 
tumours 
Germ cell tumours 
Sex cord-stromal 
tumours 
No of 
cases 
% 
No of 
cases 
% 
No of 
cases 
% 
1 <19 0 0 5 18.51 0 0 
2 20-39 48 37.5 13 48.14 3 42.85 
3 40-59 57 44.53 8 29.62 4 57.14 
4 >60 23 17.96 1 3.7 0 0 
 Total 128 100 27 100 7 100 
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DISTRIBUTION OF NON NEOPLASTIC LESIONS  
TABLE 14 Distribution of non-neoplastic lesions 
S.No Types No of cases % 
1 Follicular cyst 8 21.05 
2 Luteal cyst 4 10.52 
3 Inclusion cyst 3 7.89 
4 Endometriotic cyst 20 52.63 
5 Massive edema of ovary 1 2.63 
6 Tuboovarian abscess 2 5.26 
 Total 38 100 
 
As shown in Table: 15, the most common non neoplastic cyst diagnosed was 
endometriotic cysts (20 cases, 52.63%), followed by follicular cysts (8 cases, 
21.05%). 
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AGE OF THE PATIENTS AND SIZE OF THE NON NEOPLASTIC LESIONS: 
TABLE 15 Age of the patient and size of the non-neoplastic lesions 
S.No Type of cysts 
Age of the patient Size of the lesion 
Range Mean Range Mean 
Years Years Cms Cms 
1 Endometriotic cyst 23-70 33.6 4-12 8 
2 Follicular cyst 30-48 41.25 4-7 5.5 
3 Corpus luteal cyst 27-38 33.25 4-12 8 
4 Massive edema of ovary  48 48 5 5 
5 Tuboovarian abscess 30-38 34 5-7 6 
6 Inclusion cyst 22-77 47 6-7 6.5 
 
In the present study the mean age of the endometriotic cyst was 33.6years, of 
follicular cyst was 41.22years, of luteal cyst was 33.25years, of inclusion cyst was 
47years, of tuboovarian abscess was 47years.The mean diameter of endometriotic cyst 
was 8cms, of follicular cyst 5.5cms, of luteal cyst 8cms, of inclusion cyst was 6.5cms, 
of tuboovarian abscess was 6cms in diameter. (Table 16) 
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HISTOMORPHOLOGICAL PATTERNS OF OVARIAN LESIONS:  
 The details of the histomorphological types of benign ovarian tumours found 
in this study are given below. 
SEROUS CYSTADENOMA: 
This was the most common benign tumour found in this study. Totally, 60 
cases were reported. Serous cystadenoma accounting for 36.36% of total ovarian 
neoplasms. Peak incidence was seen in 3rd and 4th decade of life. The youngest patient 
was 20years old and oldest was 68years old. All were unilateral tumours. 
Macroscopically, the largest specimen was measured about 18x14x6cms and 
smallest was measured 5x2x2cms with a smooth external surface. Cut surface of the 
many tumours showed uniloculated cyst with smooth inner surface, containing serous 
fluid. Some tumours showed papillary excrescence from the inner surface. 
Microscopically these tumours showed cyst wall, lined by cuboidal 
epithelium, few tumours showed simple papillae lined by cuboidal cells. In a few 
cases, cysts were lined with ciliated cuboidal cells. 
SEROUS CYSTADENOFIBROMA: 
In this study, only 5 cases were reported as serous cystadenofibroma. Largest 
tumour was measured about 12x8x4cms and smallest was measured about 5x3x2cms. 
All of them were unilateral tumours. 
Macroscopically they showed solid and cystic cut surface. Solid areas are 
greyish white in colour, firm in consistency and cystic areas showed papillary 
projections from its inner surface. On microscopical examination, they showed a cyst 
wall thrown into papillae lined by cuboidal epithelium with subepithelial abundant 
fibrous tissue. 
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SEROUS BORDERLINE TUMOUR: 
Only 2 cases were reported as borderline type, seen in 3rd and 4th decade of 
life. Macroscopically, they were unilateral, cystic masses. Cut section showed solid 
and cystic areas, with inner surface lined by papillary excrescence. Microscopical 
examination showed a cyst wall lined with branching papillary fronds lined by 
stratified cuboidal cells with mild nuclear atypia with minimal stromal invasion. 
MUCINOUS CYSTADENOMA: 
Present study showed 34 cases of mucinous cystadenoma (26.77% of all 
benign tumours).All the them were unilateral tumours. Most cases occurred in 4th and 
5th decade, presented with abdominal mass. The youngest patient was 25years old and 
oldest was 70years old. 
Macroscopically, they are cystic tumours; largest tumour was measured about 
35x30x10cms and smallest measured 5x5x2cms with smooth outer surface. Cut 
surface showed multiloculated cysts containing mucoid substance with smooth inner 
surface. Microscopical examination showed a cyst wall lined by tall columnar 
epithelium resembling endocervical lining. Intracellular mucin was demonstrated with 
special stains. 
BRENNER TUMOUR: 
One case of Brenner tumour was reported in a 67 years postmenopausal 
woman, who was presenting with abdominal pain. Macroscopically it was unilateral 
and measured about 11x10x7cms. Cut surface showed solid tumour, greyish white in 
colour, firm in consistency. 
Microscopically, the tumour cells are arranged in nests surrounded by dense 
fibroblastic stroma. The tumour cell nuclei showed longitudinal grooves. (Figure13) 
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FIBROTHECOMA: 
In the present study we noted 3 cases of Fibrothecoma and two cases of 
Fibroma. All the cases were seen in 4th and 5th decade. Fibromas were small in size 
measured about 5x4x2cms. But the mean size of fibrothecomas was 12cm in 
diameter. All were unilateral tumours. Macroscopically, they were well circumscribed 
solid tumours, greyish white to yellow in colour, firm in consistency. 
On microscopical examination, fibromas were arranged in fascicles of spindle 
shaped cells with bland nuclei admixed with bundles of collagen. Fibrothecoma 
showed the tumour cells were plump oval to spindle shaped cells with eosinophilic 
cytoplasm containing bland nuclei. The slide was stained with Reticulin stain, 
reticulin fibres were demonstrated around the individual cells. (Figure 18, 19) 
BENIGN CYSTIC TERATOMA: 
In our study it contributes 13.33% of total ovarian neoplasms and 81.48% 
among germ cell tumours. Mean age at presentation was 34.5years, youngest patient 
was 15years old and oldest patient was 70years woman. All the tumours were 
unilateral except two cases, which are bilateral. 
Macroscopically the smallest tumour measured about 5x2x2cms, largest 
tumour measured about 5x2x2cms. All the cases were cystic in consistency; few cases 
were predominantly cystic and solid in consistency. In majority of the cases cut 
surface showed sebum, hair and teeth. Microscopically it showed mature elements of 
all the three germ cell layers. 
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HISTOPATHOLOGICAL PATTERN ANALYSIS OF MALIGNANT 
TUMOURS: 
Table 16 Microscopic patterns of malignant tumours 
Type of cancers Microscopical patterns No of cases 
 
Serous cystadenocarcinoma 
Complex branching papillary 
pattern 
11 
Solid sheets 7 
Mucinous cystadenocarcinoma Mixed complex papillary and 
glandular pattern 
6 
Endometrioid carcinoma Glandular pattern 1 
Clear cell carcinoma Solid sheets 1 
Granulosa cell tumour Micro and macrofollicular 
pattern 
1 
Solid sheets 1 
Yolk sac tumour Microcystic and reticular 
pattern 
1 
Metastatic tumour Nodular growth composed of 
glands 
1 
Struma carcinoid Trabecular pattern 1 
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IMMUNOHISTOCHEMICAL FINDINGS: 
Table17 Immunohistochemical findings of malignant tumours 
 
Type of tumours Immuhistochemistry  No of cases 
Poorly differentiated serous 
carcinomas 
WT-1 positive 7 
CK 7 positive 5 
Bilateral Mucinous 
cystadenocarcinoma 
CK 7 positive 4 
CK 20 negative 4 
Endometrioid carcinoma CK 7 and EMA positive 1 
Granulosa cell tumour Inhibin positive 1 
Yolk sac tumour AFP positive 1 
Dysgerminoma PLAP 1 
Metastasis CK 7 negative 1 
CK 20 positive 1 
 
SEROUS CYSTADENOCARCINOMA:  
Out of 36 ovarian malignancies, 18 cases were reported as serous 
cystadenocarcinoma. Peak incidence of age was 5th and 6th decade of life. Most of 
them were bilateral tumours. 
Macroscopically, the largest specimen was measured about 18x15x10cms and 
smallest measured as 6x6x6cms. In majority of the cases, we received irregular solid 
masses. Cut surface showed variegated in appearance with areas of haemorrhage and 
necrosis. 
Microscopic examination showed that the tumour composed of cells arranged 
in complex papillary pattern, papillae were lined by pleomorphic cells with atypical 
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nuclei infiltrating into the underlying stroma, admixed with areas of haemorrhage and 
necrosis. 
Out of 18 cases, 7(38.8%) cases were poorly differentiated type. All of them 
were presented in postmenopausal age group (more than 60years). Macroscopically, 
they were all bilateral, solid tumours with capsular breach and omental deposits were 
seen in all the cases. Microscopically, they show solid sheets of small hyper 
chromatic cells with numerous mitotic figures, few cases show syncytial aggregates of 
tumour gaint cells. All the slides of poorly differentiated type were subjected with 
immunomarker CK 7 and WT-1.WT-1 expressed nuclear positivity in all the cases, 
whereas CK 7 was positive in five cases.(Table 16,17) (Figure 4,5,6) 
MUCINOUS CYSTADENOCARCINOMA: 
Four cases of mucinous cystadenocarcinoma were reported in this study. It 
was seen in 5th and 6th decade. Out of 4 cases, 3 of them showed bilateral presentation. 
Macroscopically they were all large tumours measured about 30x20x10cms with 
bosselated surface. Cut surface showed closely packed multilocular cystic spaces 
filled with mucinous fluid admixed with greyish white solid areas showing 
haemorrhage and necrosis. 
Microscopically, they showed a tumour arranged in complex papillary pattern 
and irregular closely packed glands lined by stratified pleomorphic cells with atypical 
nuclei admixed with extracellular pool of mucin. Intracellular and extracellular mucin 
was demonstrated by special stains-Periodic acid Schiff stain. It showed magenta 
colour. All the bilateral tumours were stained by Cytokeratin 7 and CK 20 to rule out 
the gastrointestinal primary. Tumour cells exhibit CK 7 positivity, confirmed the 
ovarian origin. (Table 16, 17) (Figure7,8,9,) 
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ENDOMETRIOID CARCINOMA: 
One case of 52 year female presented with abdominal mass and pain was 
reported as endometrioid adenocarcinoma. Macroscopically, the tumour measured 
about 10x9x7cms. Cut surface showed predominantly solid areas, which is greyish 
white in colour admixed with areas of haemorrhage and necrosis. 
Microscopic examination it showed, irregular glands, lined by stratified 
columnar cells with marked pleomorphism and atypical nuclei. Micro glandular 
structures resemble that of granulosa cell tumour. Immunostainig with CK 7 and 
EMA was performed, to rule out granulosa cell tumour and they were found to be 
positive. (Table 16, 17)(Figure 10, 11) 
CLEAR CELL CARCINOMA: 
Only one case of clear cell carcinoma was reported in this study. It was seen in 
the 55years old postmenopausal women presented with abdominal pain with mass. 
Tumour measured about 20x10x8cms.It was unilateral. Macroscopically, it was a 
solid tumour, spongy in consistency admixed with massive areas of haemorrhage and 
necrosis. Microscopic examination it showed that sheets of polygonal cells with clear 
cytoplasm containing pleomorphic nuclei. Slide was stained with PAS, cytoplasm 
showed magenta colour. (Table 16)(Figure 12) 
GRANULOSA CELL TUMOUR: 
In our study we found, two cases of Granulosa cell tumours. They were seen 
in younger age group with the mean age of 30years.One patient was presented with 
bleeding per vagina with abdominal pain. Both were unilateral tumours. One tumour 
was small in size, measured 7x6x6cms whereas another one was measured about 
22x19x10cms. 
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On microscopical examination, one tumour was arranged in both micro and 
macro follicular pattern, cells were having bland nuclei with intra nuclear grooves. 
Another tumour showed solid and trabecular pattern of growth, the tumour cells 
revealed nuclear grooves. Mitotic activity was less in both the tumours. Reticulin stain 
was performed in this case and reticulin fibres were demonstrated around the each 
tumour cell clusters. Immustaining with Inhibin expressed nuclear positivity (Table 
16, 17) (Figure 14,15,16,17) 
MALIGNANT MIXED GERM CELL TUMOUR: 
Four cases were reported in our study, contributed 2.42% of all ovarian 
neoplasms. Three cases were seen in younger age group with mean age of 19years 
and one case was 47 years old woman. All the cases were unilateral tumours. Mean 
size of the tumour was 15 cms in diameters. Tumours of younger age group presented 
with a large mass. 
Macroscopically, all the tumours showed solid or solid-cystic consistency. 
Microscopically three tumours were showing Yolk sac tumour with Dysgerminoma. 
One case showed the mixture of Immature teratoma and Embryonal carcinoma. Yolk 
sac tumour showed reticular and micro cystic pattern of growth admixed with Schiller 
Dual bodies. Immunostaining with AFP showed positivity. (Table 16, 17)         
(Figure 20,21,22,23)  
METASTATIC TUMOURS: 
Two cases of metastatic tumours were reported in this study. These are 
presented in 4th and 6th decade. Both the tumours were bilateral. The mean size of the 
tumour was 8cms in diameter. Macroscopically one tumour was asymmetrically 
enlarged, cut surface showed greyish white in colour, solid in consistency. Another 
tumour had solid-cystic cut surface. 
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Microscopically both the tumours showed nodular pattern of growth 
composed of cells arranged in infiltrative, glandular pattern admixed with dirty 
necrosis. In addition to this, one tumour showed cordlike arrangement of the signet 
ring cells. This tumour designated as Krukenberg tumour and it shows PAS positivity. 
The tumour with glandular pattern of growth was subjected with Cytokeratin 20 &7. 
It showed CK 20 positivity, confirms the gastrointestinal origin. (Table16, 17)     
(Figure 24,25,26,27) 
One case of Struma carcinoid was seen 52 year postmenopausal women. 
Unilateral tumour with the size of 10cms in diameter. Cut surface showed 
multiloculated cyst containing brownish glistening solid areas. Microscopical 
examination showed tumour arranged in trabecular pattern with a focus showing 
insular pattern composed of small hyperchromatic cells intermixed with thyroid 
follicles, showing intact capsule.  
NON NEOPLASTIC LESIONS: 
Endometriotic cyst: 
This was the most common non neoplastic cyst found in this study (52.63%). 
Most commonly it was seen in 2nd and 3rd decade and abdominal pain was the 
common presentation. All were unilateral cysts with a mean size of 8cms in diameter. 
Macroscopically, most of the cysts were uniloculated with haemorrhagic content. 
Microscopical examination showed a cyst wall lined by attenuated endometrial glands 
admixed with stroma showing hemosiderophages and haemorrhages.  
Follicular cyst: 
This was the second most common lesion, contributes 21% of total non 
neoplastic lesions. The mean age of presentation was 41years.Majority of the cases 
were unilateral. The mean size of the tumour was 5.5cms in diameter. Three patients 
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were presented with abnormal uterine bleeding. Microscopically, cysts were lined by 
inner granulosa cells and outer layer of theca cells. 
Corpus Luteal cyst: 
It accounts for 10.52% of non-neoplastic lesions. The mean age of 
presentation was 30years.The mean size of the cyst was 8cms in diameter. 
Macroscopically, the cyst wall is convoluted and yellow in colour. Microscopically, it 
was lined by luteinised granulosa cells interrupted by wedges of theca lutein cells. 
One case of massive edema of ovary was reported. Cut section showed 
homogenous, glistening appearance. Microscopically, edematous ovarian stroma was 
seen, sparing the cortex. ( Figure  28, 29). 
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DISCUSSION 
INCIDENCE OF OVARIAN CANCERS: 
Incidence of ovarian cancers is more common in Western countries than Asian 
countries. A study conducted by Koonings et al[1989]3, in United States showed that 
the frequency of ovarian cancers among all gynaecological cancers was 
15.8%,whereas another study done in Nepal by Kayastha et al[2009]38 reported 9.5% 
of  incidence among 568 cases and Santhosh Kumar Mondal et al[2011]39reported 
8.7% in Eastern India. When compared to western data, our study showed a lesser 
incidence [8.2%], but correlates well with Asian statistics. 
DISTRIBUTION OF NEOPLASTIC AND NON NEOPLASTIC LESIONS: 
A study conducted by De Kroon et al [2004]40 in United States reported that 
two-third of ovarian cysts were found to be non-neoplastic. In India [Meerut], Gupta 
et al [2007]41 reported 58.79% of non-neoplastic lesions and 41.2% of neoplastic 
lesions among 282 cases, whereas another study done in Mumbai by Bhattacharya et 
al [1980]42reported that out of 270 cases, 7.41% were non neoplastic, 92.59% were 
neoplastic. The present study showed that, out of 203 cases, 38(18.71%) cases were 
non neoplastic, 165(81.28%) cases were neoplastic lesions. Our study correlates with 
the study of Bhattacharya et al, not with other studies. 
DISTRIBUTION OF BENIGN, BORDERLINE AND MALIGNANT 
NEOPLASMS: 
Major fraction of ovarian tumours in our study comprises benign tumours 
(76.96%) followed by malignant (21.81%) and borderline tumours 
(1.21%).Comparison of percentage of our results with various studies shown in 
Table18. 
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Table 18 Comparison of percentage of Benign, Borderline and Malignant 
tumours with other studies: 
S.No Authors 
Benign 
tumours 
Borderline 
tumours 
Malignant 
tumours 
1 Bhattacharya et al[1980]42 64.07% 7.41% 28.52% 
2 Koonings et al[1989]3 75.45% 3.6% 20.9% 
3 Santhosh Kumar Mondal et 
al [2011]39 
63.1% 7.3% 22.9% 
4 Gupta N et al[2007]41 72.9% 4.1% 22.9% 
5 Pilli et al [2005]43 76% 2.8% 21.2% 
6 Present study 76.96% 1.21% 21.81% 
 
Results of our study were similar to the findings of other studies (Table 19) 
but higher number of borderline cases has been reported by Santhosh Kumar Mondal 
et al39and Bhattacharya et al42. 
DISTRIBUTION OF OVARIAN TUMORS ACCORDING TO AGE:  
In the United States, Koonings et al [US] [1989] reported that 94% of benign 
tumours occurred between 20 – 29 years and 92% of malignant tumours occurred 
after sixth decade. In our study, 44.09% of benign tumours were diagnosed between 
20-40 years of age, whereas 77.77% malignant tumours occurred after fourth decade. 
Present study correlates with the studies conducted by Santhosh Kumar Mondal et al 
[Eastern India] [2011]39, Kayastha et al [Nepal] [2009]38, Bhattacharya et al [Mumbai] 
[1980]42 When compared to Western countries, our study shows earlier age of onset of 
malignant tumours.  
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In our study we noted that most of the epithelial tumours were seen between 
4th and 5th decade. Our result was comparable with the studies conducted in India by 
Santhosh Kumar Mondal et al[2011] 39and Bhattacharya et al[1980]42.But the studies 
carried out in Western population by Koonings et al[US][1989]3 and Di Bonito et 
al[Italy] [1988]44 found that epithelial tumours were more common after 50 years. 
Cannistra et al[England][2004]9reported that 58% of the germ cell tumours occurred  
before 30 years and Santhosh Kumar Mondal et al[Eastern India][2011]39 reported 
67.77%.These observations correlate with our study where 66.65% of the germ cell 
tumours occurred in the age group of less than 30years. 
MODE OF PRESENTATION: 
In the present study we noted that almost half of the cases (47.27 %) presented 
with combined abdominal pain and mass and 37.17% of the cases presented only with 
abdominal pain. Comparative analysis was done with various studies and it was 
shown in Table 19 
Table 19 Mode of presentation of cases of various studies in comparison with our 
study 
S.No 
Mode of 
presentation 
Authors 
Maheswari  et al Couto et al Pilli et al Present study 
1 Abdominal pain 39% 40% 70% 31.51% 
2 Abdominal mass 71% 90% 63% 13.93% 
3 Bleeding per vagina 3% 39% 10% 3.03% 
4 Ascites 3% 4.9% 24% 0% 
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Our study correlated well with the studies done by Pilli et al[Belgaum][2005] 
and Kayastha et al [Nepal][2009]38,where abdominal pain was the commonest 
symptom, and cases presenting with abdominal mass were less in the present study 
compared to the studies carried out by Maheswari et al[Aligarh][1994]16and Couto et 
al[Goa][1993]45.Studies conducted in Western world by Bankhead et al[UK][2008]46 
and Goff et al[US][2004]47showed that abdominal distension was the commonest 
symptom. 
LATERALITY: 
 Present study showed that 89.7% were unilateral tumours and 10.3% were 
bilateral, thus correlating well with other studies conducted by Couto et 
al[Goa][1993]45and Prabhakar et al[Amristar][1989]1 whereas Koonings et al[US]3 
and Kar et al[Cuttack][2005]48 found more number of bilateral tumours 22% and 
26.8% respectively. 
Table 20 Comparison of laterality of neoplastic lesions with other studies 
 
As shown in Table 20 present study showed that majority of benign tumours 
(97.63%) were unilateral and most of malignant tumours were bilateral(38.88%).  
This observation is in concurrence with the above mentioned studies. 
Sino Authors  Benign(%) Borderline(%) Malignant(%) 
U/L B/L U/L B/L U/L B/L 
1 Jha et al [2008]49 93.33 6.67 0 0 57.7 42.3 
2 Kuladeepa  et 
al[2011]50 
93.75 6.25 80 20 68.42 31.58 
3 Kayastha et al[2009]38 93.02 6.97 100 0 33.33 66.66 
4 Present study 97.63 2.36 100 0 61.11 38.88 
68 
 
GROSS FINDINGS: 
In our study, we noted that out of 165 neoplastic cases, 66.99% of the tumours 
were cystic, 10.3% of the tumours were solid and 22.66% of the tumours had both 
solid and cystic cut surface. All the benign tumours were cystic and all the malignant 
tumours showed either solid or solid-cystic cut surface. This observation was 
correlated with the studies by Koonings etal [US] [1989]3, Gupta et al [Meerut] 
[2007]41, Couto et al [Goa] [1993]45. 
DISTRIBUTION OF OVARIAN TUMORS ON THE BASIS OF 
MICROSCOPICAL DIAGNOSIS: 
In our study we found that Surface epithelial tumours comprised 77.57% of all 
ovarian neoplasms, Germ cell tumours contribute 16.36%, Sexcord stromal tumours 
contribute 4.24% and metastatic tumours were 1.21%.This result correlates with the 
studies done in Western population by Koonings et al[US][1989]3,Di Bonito et al 
[Italy][1988]44,in Asian  population  by Samina Zaman et al[Pakistan]51,Kayastha et 
al[Nepal]38,Pilli et al[India]43.But in contrast Gupta et al[Meerut][2007]41 found  
lower incidence of epithelial tumours and a higher incidence of germ cell and 
metastatic tumours .  
Koonings et al3 stated that epithelial tumours contribute 40% of the all benign 
neoplasms and 85% of malignant neoplasms. Di Bonito et al44 also reported that 50% 
of the benign tumours and 94.4% of the malignant tumours were of epithelial origin. 
This is in contrast to our study in which epithelial tumours comprised 78.74% of total 
benign neoplasms and 72.22% of malignant neoplasms. This observation was 
comparable with the studies conducted by Samina Zaman et al51, Swamy et al, Pilli               
et al43. 
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Present study showed that germ cell tumours contribute 17.32% of benign 
neoplasms and 13.88% of malignant neoplasms. This result was similar to the studies 
done in Indian population by Couto et al45 and Prabhaker et al1. But Koonings et al3 
reported more number of benign (45%) and less number of malignant germ cell 
tumours (4.3%).Di Bonito et al44 also found that 27.5% of benign and 2.8% of 
malignant germ cell tumours. This observation was not in concurrence with our study. 
SEROUS TUMOURS: 
DISTRIBUTION OF SEROUS TUMORS WITH RESPECT TO ALL 
OVARIAN TUMORS 
Studies conducted by Couto et al45 ,Kayastha et al38 and Pilli et al43observed 
42.5%, 40% and 42.9% of serous tumours among total ovarian neoplasms 
respectively. This observation correlates with our study (39.39%), but in contrast to 
our study, Misra et al [UP] [1991]52(55.8%) reported higher incidence of serous 
tumours .The present study showed, out of 85 cases 58 cases (69.4%) were serous 
cystadenomas, 5 cases were serous cystadenofibromas, one case was papillary serous 
cystadenoma, 2 cases were borderline tumours and remaining 18 cases were 
carcinomas. Saxena HMK et al [1980]53and Maheswari et al [1994]16demonstrated 
72.03% and 69.8% of serous cystadenomas in their studies respectively analogous to 
our study. Microscopically benign tumours showed a cyst wall lined by cuboidal 
epithelium with a few cases (5 cases) showed ciliated cells. In contrast, Krigman et al 
[US] [1994]54 observed more ciliated cells. 
        In our study Serous cystadenocarcinoma constitutes 21.17% of all serous 
tumours which was comparable to the study of Maheswari et al ( 19.8% ).In contrast 
to our study, Krigman et al54 reported 36% of malignant serous tumours .All the cases 
either showed solid or solid- cystic cut surface with areas of haemorrhage and 
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necrosis  as observed by Krigman et al54.Out of 18 cases 7 cases were poorly 
differentiated type and majority of these cases were postmenopausal women(above 60 
years of age) with  bilateral presentation. Dehari et al [US] [2007]55 reported that two 
third of poorly differentiated tumours were bilateral which correlates with our study. 
All the seven cases showed nuclear positivity with WT-1 marker, 5cases expressed 
membrane positivity with CK-7.This observation was similar to the study done by 
Hussaini et al[US][2004]56.It was a immunohistochemical study done among 76 
cases, all the 38 cases of ovarian serous carcinomas, showed WT-1 nuclear positivity. 
Gupta et al [2007]41 reported that borderline tumours contribute 1% of total 
ovarian neoplasm which was comparable with our study (1.2%). But Pilli et al 
[2002]44 and Santhosh Kumar Mondal et al [2011]39 reported higher incidence of 
borderline tumors. Microscopically they showed epithelial stratification, nuclear 
atypia and minimal stromal invasion. McKenney et al [2006]57 found that presence of 
micro invasion was associated with poor prognosis. 
MUCINOUS TUMOURS: 
COMPARISON OF MUCINOUS TUMOURS WITH RESPECT TO ALL 
OVARIAN TUMORS: 
The present study showed that mucinous tumours accounting for 24.24% of all 
ovarian neoplasm. This observation was in accordance with the studies by Couto et 
al[1993]45,Gupta et al[2007]41but Misra et al[1991]52 reported less number of 
mucinous tumours in comparison with our study. Out of 40 mucinous tumours 36 
(90%) were benign, 4 (10%) cases were malignant. There were no borderline tumours 
reported. But Koonings et al[1989]3demonstrated less number of (74.5%)benign 
tumors,10% of borderline tumours and more number of (15%) malignant tumours as 
compared with our study. Macroscopically, size of the tumours varied from 5cms in 
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diameter to 35 cms in diameter. Tyagi SP et al [1993]58 reported a case with a tumour 
of 47 cm in diameter, and showed 10 % bilateralism among mucinous tumors. In the 
present study we noted 6.4 % bilateralism. All these tumours were malignant. In our 
study 89.8% of the tumours were multilocular this is comparable with the study done 
by Maheswari et al [1994]16(83.9 %). Microscopically, benign tumours showed a cyst 
wall lined by tall columnar cells with apical mucin which was demonstrated by 
special stain. Krigman et al [US] [1994]54 observed all the malignant tumours and 
10% of the benign tumours were of intestinal type. However in the present study all 
the benign tumours were lined by endocervical type epithelium and malignant 
tumours were lined by intestinal type epithelium. Vang et al [US] [2006]59 analysed, 
CK 7 and CK 20 expression among 179 mucinous tumours and found that primary 
mucinous carcinomas exhibit CK 7 positivity and C K 20 negativity. In our study all 
the bilateral mucinous carcinomas were subjected with CK 7 & CK 20 to rule out the 
intestinal metastatic deposits and found to be CK 7 positive and CK 20 negative. 
 OTHER SURFACE EPITHELIAL TUMOURS: 
         In our study endometrioid carcinoma contributes to 0.78 % of surface epithelial 
tumors.This incidence correlates with study conducted by Prabakar et al[1989]1.He 
demonstrated 1.1% of endometrioid carcinomas whereas studies by Maheswari et 
al[1994]16 and Dawar et al[2004]60 reported higher incidences(3.65%&5.7% 
respectively).Vigano et al[2008]18 demonstrated that association of endometriosis in  
10% of  the  tumours , but no associated endometriosis was seen in our case 
Immunomarkers of CK 7 and EMA were  positive in our study, similar to the study 
done by Riopel et al [1998]61. 
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In our study we reported one case of clear cell carcinoma. It contributes, 
0.78% of surface epithelial tumours, which correlates with the study of Maheswari et 
al16 (0.79%). 
There was one case of benign Brenner tumour accounting for 0.78 % of 
surface epithelial tumours. But Krigman et al [1989]3and Maheswari et al [1994]16 
reported 2%, and 1.1% respectively. Microscopically the tumour cells were arranged 
in nests surrounded by fibrous stroma. The tumour cells resemble that of urothelial 
cells as stressed by Balasatw et al [1997]62. 
GRANULOSA CELL TUMOR: 
The present study showed that granulosa cell tumour contributes 1.21 % (2 
cases) of all ovarian neoplasms. The incidence was less compared to the study done 
by Ramachandra et al [1972]63(2.7 %). Mean age of presentation in our study was 
30.5 years which was less compared to the study done by Ayhan et al[2009]64 (47 
years). Macroscopically, one tumour was measured 22 cms in diameter; another was 
measured 7 cms in diameter. Ayhan et al64 stated that the tumours larger than 15 cm 
had poor prognosis. Microscopically one tumour showed solid pattern, another 
tumour showed combined micro follicular and macro follicular patterns. Both the 
tumours showed low mitotic index. Stuart et al [2003]21 stated that microscopical 
patterns do not predict the prognosis and he also demonstrated Inhibin positivity in all 
the cases. In the present study Inhibin immunostaining was performed and found to be 
positive. 
BENIGN CYSTIC TERATOMA: 
Our study showed that benign cystic teratoma contributes 13.33% of total 
ovarian neoplasm and 81.48% of total germ cell tumours .This observation correlates 
with the studies conducted in India by Couto et al45,Tyagi et al58 with an incidence of 
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15.45%, 18.46% of total ovarian tumours respectively. In a study conducted by 
Koonings et al3, it contributed 95 % all germ cell tumours which was higher than our 
study. The present study showed 9 % tumours were bilateral which was similar to a 
study conducted by Tyagi et al58 where 8.33% of tumours were bilateral. Majority of 
the cases in our study were reported in second and third decades of life as compared 
to the study done by Couto et al45. 
MALIGNANT MIXED GERM CELL TUMOR:  
Malignant mixed germ cell tumours contributed about 2.4% of all ovarian 
neoplasms. Similar studies carried out by Prabakar et al1 and Gupta et al41 showed an 
incidence of 0.78% and 0.59% respectively which are less as compared with our 
study. We had 3 cases of yolk sac tumour with dysgerminoma and one case of 
immature teratoma with embryonal carcinoma. Kurman et al[1976]30studied about 30 
ovarian mixed Germ cell tumours and showed that Dysgerminoma was the most 
common constituent followed by Yolk sac tumour which correlates with our study. 
He also stated that if more than one third of a stage I neoplasm composed of Yolk sac 
tumour or Choriocarcinoma or Grade III Immature teratoma showed poor prognosis. 
In the present study we observed that more than one third of the tumour was 
composed of Yolk sac tumour in all the slides. 
MISCELLANEOUS TUMOURS: 
Metastatic tumours: 
One case of Krukenberg tumour and another case of intestinal metastatic 
deposits were seen. It accounts for 1.21% of total neoplasm. But studies done by 
Couto et al45, Mishra et al52 and Prabakar et al1 showed an incidence of 1.46 %,                     
1.07 % , 1.57 % respectively which were higher than our study. Krukenberg tumour 
was bilateral similar to a study done by Powari et al[2003]31.Microscopically diffuse  
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infiltration of tumour cells were seen, they arranged in nests or pseudo glandular 
pattern. In Krukenberg tumour, many signet ring cells were seen in oedematous 
ovarian stroma. The tumour cells were PAS positive. Holtz and Hart 
[1982]65demonstrated that out of 27 cases 16 cases were PAS positive. Metastatic 
tumour showed Cytokeratin 20 positivity and Cytokeratin 7 negativity, confirming the 
gastrointestinal origin. This observation was similar to the study done by Vang et al 
[2006]66and Baker et al [2005]67.Theyshowed that all the cases of metastatic tumours 
of intestinal origin were CK 20 positive and CK 7negative.  
                 One case of Struma carcinoid was reported.Microscopical examination 
showed that in more than half of the tumour, the small cells were arranged in 
trabecular pattern admixed with thyroid follicles. Robby SJ et al [1980]68analysed 50 
cases and stated that the most common histological pattern present in Struma 
carcinoid was trabecular pattern. 
NON NEOPLASTIC LESIONS: 
INCIDENCE: 
Table 21 Comparison of incidence of non neoplastic lesions with other studies. 
S.No Non neoplastic cysts 
Authors 
Samina Zaman et al51 Pudasaini et al69 Present study 
1 Follicular cyst 22.24% 4.8% 3.9% 
2 Corpus luteal cyst 34.83% 13.7% 1.9% 
3 Endometriotic cyst 10.78% 5.9% 9.8% 
 
In the present study endometriotic cyst was the most common non-neoplastic 
lesion, contributes 9.8% of total ovarian lesions(52.63% of non-neoplastic lesions). 
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This result contradicts other studies done by Samina Zaman et al[2010] 51and Gupta et 
al[2007]41where almost half of the cases were contributed by Luteal cyst.(Table 21) 
MEAN AGE OF NON NEOPLASTIC LESIONS 
In the present study we found that they were commonly occurred between 3rd 
and 4th decade. This observation correlates with the studies conducted by Samina 
Zamina et al [2010]51and Pudasaini et al [2011]69. (Table 22) 
Table 22 Comparison of mean age of non-neoplastic lesions with other studies 
 
GROSS FINDINGS: 
Table23 Comparison of mean size of non neoplastic lesions with other studies 
 
As shown in Table 23 in our study showed that the mean size of the cysts was 
slightly larger than the above mentioned studies. In the present study abdominal pain 
was the commonest symptom, which was comparable with the studies by Gupta et al41 
and Wasim et al70. 
S.No Non neoplastic cysts 
Authors 
Mean age(years) 
Samina Zaman et al Pudasaini et al Present study 
1 Endometriotic cyst 30.28 35.28 33.6 
2 Follicular cyst 37.67 39.1 41.25 
3 Luteal cyst 35.41 32.12 33.25 
S.No 
 
Non neoplastic cysts 
Authors 
Size (cms) 
Samina Zaman et al51 Gupta et al41 Present study 
1 Endometriotic cyst 5.98 5.5 8 
2 Follicular cyst 3.95 5.2 5 
3 Luteal cyst 3.76 6.1 8 
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SUMMARY AND CONCLUSION 
             A histopathological study of ovarian non neoplastic and neoplastic lesions  
was undertaken in the Department of Pathology Tirunelveli medical college to know 
the occurrence of different types of ovarian lesions in this region and found to be  
correlated with similar other studies conducted among  Western and  Asian population  
with only a few exceptions. 
          In the present study 203 ovarian lesions were analysed for the period of three 
years January 2008 to December 2010. Ovarian tumours were classified based on 
recent WHO classification. 
          Benign tumours were the major component of ovarian tumours constituting 
76.96 % followed by malignant tumours (21.81 %) and borderline tumours (1.21%)  
        Surface epithelial tumours were the major group (77.57%), followed by germ 
cell tumours (16.36%) and sex-cord stromal tumours (4.4%). 
These tumours occurred in all age group but most of the tumours were in the 
age group between 40-59years.Benign and borderline tumours occurred in younger 
age group whereas malignant tumours were common after 40years.The occurrence of 
malignancy is earlier than in Western statistics. Surface epithelial tumours occurred in 
all age groups. Germ cell tumours were common in younger age group. 
           Most of the tumours were unilateral 89.7%.and 10.3% of tumours were 
bilateral. Bilaterality was common among serous tumours. Most common presentation 
was abdominal pain. 
The tumour varied in size, largest tumour was Mucinous cystadenoma 
measuring 35x30x18cms and smallest tumour was benign cystic teratoma measuring 
5x2x2cms. Larger size was seen in benign mucinous tumours and malignant tumours. 
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All the benign tumours were cystic in consistency whereas, all malignant 
tumours had either solid or solid-cystic cut surface. 
         The commonest benign tumour was serous cystadenoma (47.24%) and the most 
common malignant tumour was serous cystadenocarcinoma (50%). 
         The occurrence of malignancy was more common in serous tumours 21.27% as 
compared to mucinous tumours 15%. Prevalence of poorly differentiated serous 
carcinoma was found to be high. 
         Germ cell tumours formed the second largest group (16.36%).Benign cystic 
teratoma was the commonest histological type. Malignant mixed Germ cell tumours 
contributed 1.81% of all ovarian neoplasms. One case was showing a rare 
combination of immature teratoma with embryonal carcinoma. 
Two cases of granulosa cell tumours were reported. One case was presented 
with larger tumour size and solid pattern of growth with intact capsule. 
         Two cases of metastatic tumours were seen. One was Krukenberg tumour; 
another one was metastatic deposits from intestine. 
All malignant tumours of our study showed capsular breach and areas of 
necrosis and haemorrhage except granulosa cell tumour and Krukenberg tumour. 
Immunomarkers were applied in equivocal cases like all poorly differentiated 
serous carcinomas, bilateral mucinous carcinomas, endometrioid carcinoma, Germ 
cell tumours, and metastatic tumours to confirm the diagnosis. Ancillary studies –
Special stains and Immunohistochemistry provide a valuable information for 
confirming the diagnosis.  
         Out of 203 ovarian lesions, 38 cases were non neoplastic lesions. Endometriotic 
cyst was most common comprising of 20cases (52.63%), followed by follicular cysts 
(21.05%). 
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       Majority of the non-neoplastic lesions were unilateral cysts. Most commonly 
occurred in third decade and all the lesions were below 10cms.Most commonly 
presented with abdominal pain. 
     Ovaries are prone for occurrence of neoplasms which at the older age group, it 
gives enormous mental burden and economic drain for the individual. In the younger 
age group it may hinder the active life. Hence it is essential to differentiate neoplasms 
from non-neoplastic conditions and to know the prevalence of common ovarian 
neoplasms in a tertiary care set up. In our study both non neoplastic and neoplastic 
lesions were analysed based on age, clinical features, laterality, gross findings and 
histological studies. They correlated well with the studies undertaken in different parts 
of India both in frequency and prevalence. 
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Figure 4 Poorly differentiated serous carcinoma
solid, greyish white mass with capsular breach.
Figure 5 Poorly differentiated serous carcinoma
sheets of tumour cells containing
-Cut surface showing irregular,  
 
-Photomicrograph shows
 irregular hyperchromatic nuclei admi
necrosis. (H&E 100 X ) 
 
 
 solid 
xed with 
 Figure 6 Poorly differentiated carcinoma- Photomicrograph showing strong 
membrane positivity of tumour cells for CK 7. (Immunostain CK 7 100 X ) 
 
 
Figure 7 Mucinous cystadenocarcinoma- Gross picture showing multiloculated 
closely packed cysts containing mucoid material. 
 Figure 8 Mucinous cystadenocarcinoma- Photomicrograph shows tumour 
composed of  irregular glands with back to back arrangement. Inset showing PAS 
Positivity (H&E 100 X ) Inset (PAS 400 X ) 
 
Figure 9 Mucinous cystadenocarcinoma-Photomicrograph shows strong 
membrane positivity of tumour cells with CK 7. (Immunostain CK 7 100 X ) 
 Figure 10 Endometrioid carcinoma- Photomicrograph showing tumour arranged 
in microglandular pattern lined by stratified columnar cells. (H&E 100 X ) 
 
Figure 11 Endometrioid carcinoma-Photomicrograph showing strong membrane 
positivity of tumour cells for Epithelial membrane antigen. (Immunostain EMA 100 X) 
  
Figure 12 clear cell carcinoma-Photomicrograph showing diffuse sheets of tumour 
cells, containing clear cytoplasm with irregular atypical nuclei. Inset showing 
Cytoplasmic PAS Positivity (H & E 100 X), Inset (PAS 400 X )  
  
 
 
 
 
 
 
 
 
 
 
Figure 13 Brenner tumour-Photomicrograph showing tumour,  composed of   
solid nests of cells in a dense fibrous stroma. Inset showing longitudinal groove in 
the nuclei. (H & E 100 X ) Inset (H&E 400 X ) 
 Figure 14 Granulosa cell tumour showing solid-cystic cut surface. Solid areas are 
greyish white to yellow in colour, admixed with thin walled cysts filled with mucoid 
material. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Granulosa cell tumour-Photomicrograph showing tumour cells 
arranged in microfollicular pattern. (H & E 100X) 
Figure 16 Granulosa cell tumour
surrounded by reticulin fibres. 
Figure 17 Granulosa cell tumour
Alpha Inhibin 
- Reticulin stain showing tumour cell clusters 
(Reticulin stain 100 X )
- Tumour cells exhibiting nuclear positiv
(Immunostain-Inhibin 100 X) 
 
 
 
ity with 
 Figure 18 Fibrothecoma- Cut surface showing well circumscribed, uniformly solid 
tumour, greyish white in colour. 
Figure 19 Fibrothecoma- Photomicrograph showing tumour composed of fascicles 
of plump spindle shaped cells (H & E 100 X ) 
 Figure 20 Malignant mixed germ cell tumour -Cut surface showing solid  
variegated appearance. 
 
Figure 21 Dysgerminoma- Photomicrograph showing solid sheets of tumour cells 
admixed with lymphocytic infiltration. (H & E 100 X) 
Figure 22 Yolk sac tumour- Photomicrograph showing tumour arranged in 
microcystic pattern. Inset showing Schiller Dual body (H & E 100 X ) Inset                      
(H & E 400 X ) 
 
Figure 23 Yolk sac tumour exhibiting nuclear and cytoplasmic positivity with 
Alpha fetoprotein. Inset showing Schiller Dual body. (Immunostain AFP 100 X ) 
Inset (Immunostain AFP 400 X) 
 Figure 24 Ovarian Metastatic deposits- Photomicrograph showing tumour 
arranged in nodular infiltrative pattern composed of glandular structures.                   
(H & E 40 X ) 
 
Figure 25 Ovarian Metastatic deposits –Tumour cells exhibiting weak membrane 
positivity with CK 20. (Immunostain CK 20 100 X ) 
 Figure 26 Krukenberg tumours- Cut surface showing solid homogenous 
appearance, greyish white in colour. 
 
Figure 27 Krukenberg tumour- Photomicrograph showing tumour cells arranged 
in cords, nests composed of signet ring cells. Inset showing intracytoplasmic PAS 
positivity. (H & E 100 X ) Inset (H & E 400 X ) 
 Figure 28 Massive edema of ovary –Cut surface showing homogenous solid 
glistening appearance with peripheral rim of normal tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 Massive edema of ovary –Photomicrograph showing edematous ovarian 
stroma sparing the cortex. (H & E 100 X) 
M N YES NO ABD.MASS ABD PAIN BLEEDING PV SIZE(cms) SOLID CYSTIC S & C
1 46699 3    2008    27 M NO ABD PAIN UL 5X5X2 C MUCINOUS CYSTADENOMA -
2 50011 13  2008 42 M NO ABD.MASS ABD PAIN UL 9X8X6 S & C ENDOMETRIOTC CYST -
3 46700 31  2008 51 M NO ABD PAIN UL 9X4X3 S SEROUS CYSTADENOCARCINOMA -
4 46444 48  2008 43 M NO ABD PAIN UL 11X7X3 C SEROUS CYSTADENOMA -
5 44976 52  2008 60 M NO ABD.MASS UL 10X6X5 C MUCINOUS CYSTADENOCARCINOMA PAS-POSITIVE
6 50172 58  2008 65 M NO ABD.MASS ABD PAIN UL 19X14X7 C MUCINOUS CYSTADENOMA -
7 42740 70  2008 70 M NO ABD.MASS ABD PAIN UL 20X17X5 C MUCINOUS CYSTADENOMA PAS-POSITIVE
8 42748 137  2008 38 M NO ABD PAIN UL 6X4X2 C  SEROUS CYSTADENOMA -
9 46633 221  2008 40 M NO ABD PAIN UL 5X3X2 C DERMOID CYST -
10 46870 228  2008 42 M NO ABD PAIN UL 7X7X3 C INCLUSION CYST -
11 245 384  2008 38 M NO ABD.MASS ABD PAIN UL 6.5X5X2 S & C SEROUS CYSTADENOMA -
12 337 412  2008 23 N NO ABD.MASS UL 8X5X3 S & C ENDOMETRIOTIC CYST -
13 876 435  2008 48 M NO ABD.MASS ABD PAIN UL 10X6X6 S & C YOLK SAC TUMOR AFP-Positive
14 1589 493  2008 33 M NO ABD PAIN UL 7.5X5.5X4 C MUCINOUS CYSTADENOMA -
15 2939 524  2008 60 M NO ABD.MASS ABD PAIN UL 18X12X6 S & C  SEROUS CYSTADENOCARCINOMA -
16 3042 561  2008 25 M YES ABD PAIN BLEEDING PV UL 5X5X2 C SEROUS CYSTADENOMA -
17 3378 683  2008 18 N NO ABD PAIN UL 15X8X8 S MIXED GERM CELL TUMOR AFP-Positive
18 4890 742  2008 35 M NO ABD PAIN UL 6X3X2 C SEROUS CYSTADENOMA -
19 4915 781  2008 22 M NO ABD PAIN UL 7X4X3 S & C INCLUSION CYST -
20 5001 821  2008 52 M NO ABD.MASS ABD PAIN UL 10X9X7 S & C ENDOMETRIOID CARCINOMA EMA-Positive
21 5247 859  2008 45 M NO ABD PAIN BLEEDING PV UL 4X3X2 C ENDOMETRIOTIC CYST -
22 5377 935  2008 44 M NO ABD PAIN UL 5X4X2 S FIBROMA -
23 5979 950  2008 45 M NO BLEEDING PV UL 5X4X2 C SEROUS CYSTADENOMA -
24 6621 975  2008 38 M NO ABD PAIN UL 5X2X1 C SEROUS CYSTADENOMA -
25 7731 1048 2008 25 M NO ABD PAIN UL 11X5X5 C SEROUS CYSTADENOMA -
26 7924 1093 2008 50 M NO ABD.MASS ABD PAIN UL 30X25X5 C MUCINOUS CYSTADENOMA -
27 8612 1108 2008 45 M YES ABD PAIN UL 6X3X2 C SEROUS CYSTADENOMA -
28 9960 1114 2008 37 M NO ABD PAIN UL 10X6X5 C MUCINOUS CYSTADENOMA -
29 10007 1333 2008 45 M NO ABD.MASS ABD PAIN UL 15X4X5 S FIBROTHECOMA Reticulin-positive
30 10098 1347 2008 53 M NO ABD.MASS ABD PAIN UL 30X20X10 S&C MUCINOUS CYSTADENOCARCINOMA CK 7 positive &CK 20 negative
31 11003 1413 2008 77 M NO ABD PAIN UL 6X5X3 C INCLUSION CYST -
32 21267 1446 2008 60 M NO ABD.MASS ABD PAIN BL 8X6X2 S SEROUS CYSTADENOCARCINOMA -
33 24350 1464 2008 40 M NO ABD PAIN UL 5X3X2 S & C  SEROUS CYSTADENOFIBROMA -
34 25000 1467 2008 40 M NO BLEEDING PV UL 4X3.5X1 C FOLLICLE CYST -
35 26171 1509 2008 25 N NO ABD PAIN UL 7X3X2 C DERMOID CYST -
36 23667 1538 2008 23 M NO ABD PAIN UL 4X3X2 C ENDOMETRIOTIC CYST -
37 33803 1549 2008 29 M NO ABD PAIN UL 6X5X4 C DERMOID CYST -
38 34515 1551 2008 25 M NO ABD PAIN UL 6X5X4 C DERMOID CYST -
39 35804 1558 2008 33 M NO ABD PAIN UL 9X6X4 C MUCINOUS CYSTADENOMA -
40 33383 1562 2008 44 M NO ABD PAIN UL 6X5X5 C SEROUS CYSTADENOMA -
41 31004 1566 2008 33 M NO ABD PAIN UL 6X5X5 C MUCINOUS CYSTADENOMA -
42 32417 1584 2008 39 M NO ABD.MASS ABD PAIN BL 18X15X10 S & C SEROUS CYSTADENOCARCINOMA -
43 34977 1622 2008 46 N NO BLEEDING PV UL 6X4X3 C SEROUS CYSTADENOMA -
44 35072 1623 2008 37 M NO BLEEDING PV BL 6X3X2 C FOLLICLE CYST -
45 34516 1692 2008 45 M NO ABD.MASS ABD PAIN UL 20X18X16 C MUCINOUS CYSTADENOMA -
46 38809 1718 2008 23 M NO ABD PAIN UL 4X3X2 C ENDOMETRIOTIC CYST -
47 36962 1723 2008 38 M NO ABD PAIN UL 7X5X4 S TUBOOVARIAN ABSCESS -
48 36950 1727 2008 31 M YES ABD PAIN UL 5X2X2 C ENDOMETRIOTIC CYST -
49 37768 1741 2008 67 M NO ABD.MASS UL 12X9X3 C SEROUS CYSTADENOMA -
50 39225 1842 2008 45 M NO ABD.MASS UL 12X10X5 C SEROUS CYSTADENOMA -
51 41643 1857 2008 30 M NO ABD.MASS UL 15X15X5 C SEROUS CYSTADENOMA -
52 47277 1858 2008 55 M NO ABD.MASS BL 11X4X4 S SEROUS CYSTADENOCARCINOMA -
53 40733 1911 2008 44 M NO ABD.MASS UL 2X11X8 S FIBROTHECOMA Reticulin-positive
54 42872 1962 2008 30 M NO ABD.MASS UL 7X6X3 C MUCINOUS CYSTADENOMA -
55 45890 2020 2008 18 M NO ABD.MASS ABD PAIN UL 22X18X9 S MIXED GERM CELL TUMOR -
56 43557 2023 2008 68 M NO ABD.MASS UL 15X9X8 C SEROUS CYSTADENOMA -
57 45745 2074 2008 38 M NO ABD.MASS ABD PAIN UL 35X30X10 C MUCINOUS CYSTADENOMA -
58 47826 2086 2008 40 M NO ABD.MASS ABD PAIN UL 14X8X2 C SEROUS CYSTADENOMA -
59 43079 2102 2008 48 M NO ABD.MASS UL 5X4X3 C SEROUS CYSTADENOMA -
60 50749 2323 2008 27 M NO ABD.MASS UL 7X6X5 C SEROUS CYSTADENOMA -
61 50677 2324 2008 30 M NO ABD.MASS UL 20X13X7 C MUCINOUS CYSTADENOMA -
62 48027 2343 2008 52 M NO ABD.MASS ABD PAIN UL 10X10X5 S&C STRUMA CARCINOID -
63 50355 2344 2008 23 M NO ABD.MASS ABD PAIN UL 18X14X6 C SEROUS CYSTADENOMA -
64 41929 2345 2008 66 M NO ABD.MASS ABD PAIN BL 6X5X5 S  SEROUS  CYSTADENOCARCINOMA-PD WT 1 positive & CK 7 negative
65 51051 2380 2008 60 M NO ABD.MASS UL 12X12X6 C SEROUS CYSTADENOMA -
66 222 109   2009 70 M NO ABD PAIN UL 5x5x5 C DERMOID CYST -
67 1850 112   2009 22 N NO ABD.MASS UL 12x8x4 S&C SEROUS ADENOFIBROMA -
68 53105 128   2009 58 M NO ABD.MASS UL 8x6x3 C SEROUS CYSTADENOMA -
OTHER STUDIESMICROSCOPIC DIAGNOSISS.No IP No HPE No AGE(yrs) PARITY
EXOGENOUS 
HORMONAL INTAKE
CLINICAL PRESENTATION LATERALITY GROSS
69 3839 222   2009 35 M NO ABD PAIN UL 7X5X3 C DERMOID CYST -
70 4081 225   2009 42 M NO ABD PAIN UL 7X5X3 C SEROUS CYSTADENOMA -
71 7151 240   2009 32 M NO ABD.MASS ABD PAIN UL 8X6X3 C MUCINOUS CYSTADENOMA -
72 5325 380  2009  27 M NO ABD PAIN UL 7X6X4 S&C DERMOID CYST -
73 3034 385  2009 23 M NO ABD.MASS UL 13X8X6 S&C DERMOID CYST -
74 9609 499  2009 32 M NO ABD.MASS UL 16X9X4 S&C SEROUS CYSTADENOMA -
75 7954 509  2009 30 M NO ABD PAIN UL 9x7x6 C DERMOID CYST -
76 10030 562  2009 19 N NO ABD.MASS ABD PAIN UL 11x10x5 S&C DERMOID CYST -
77 10538 642  2009 27 M NO ABD PAIN UL 5x4x4 C SEROUS CYSTADENOMA -
78 10902 673  2009 65 M ABD PAIN BL 6X5X3 S&C METASTATIC DEPOSITS CK 7 Negative &CK 20 positive
79 10538 692  2009 47 M YES BLEEDING PV UL 4X4X4 C FOLLICULAR CYST -
80 11079 786  2009 40 M NO ABD PAIN UL 6X5X4 C FOLLICULAR CYST -
81 15808 860  2009 42 M NO ABD PAIN UL 5X5X4 S&C SEROUS CYSTADENO FIBROMA -
82 16128 905  2009 43 M NO ABD PAIN UL 5X3X3 C FOLLICULAR CYST -
83 16182 906  2009 42 M NO ABD.MASS ABD PAIN UL 17X15X8 C SEROUS CYSTADENOMA -
84 11883 924  2009 50 M NO ABD.MASS ABD PAIN UL 17X12X8 C MUCINOUS CYSTADENOCARCINOMA PAS-Positive
85 17095 937  2009 45 M NO ABD PAIN BL 6X6X5 C FOLLICULAR CYST -
86 20789 1008 2009 25 M NO ABD PAIN UL 7X6X4 C SEROUS CYSTADENOMA -
87 19837 1053 2009 40 M NO ABD PAIN UL 5X4X3 C SEROUS CYST -
88 20154 1083 2009 32 M NO ABD.MASS ABD PAIN UL 10X6X4 C ENDOMETRIOTIC CYST -
89 18177 1095 2009 44 M NO ABD PAIN UL 5X5X5 C SEROUS CYSTADENOMA -
90 24820 1239 2009 32 M NO ABD.MASS ABD PAIN UL 20X14X6 C MUCINOUS CYSTADENOMA -
91 29654 1300 2009 30 M NO ABD PAIN UL 5X4X4 S&C TUBOOVARIAN ABCESS -
92 24559 1328 2009 55 M NO ABD PAIN BL 7X7X5 S SEROUS CYSTADENOCARCINOMA -
93 23656 1410 2009 45 M NO ABD.MASS ABD PAIN UL 8X4X4 S SEROUS CYSTADENOCARCINOMA -
94 22136 1411 2009 50 M NO ABD.MASS UL 10X5X5 C MUCINOUS CYSTADENOMA -
95 25350 1441 2009 26 N NO ABD PAIN UL 6X4X4 S&C ENDOMETRIOTIC CYST -
96 28149 1473 2009 55 M NO ABD PAIN UL 5X5X5 C SEROUS CYSTADENOMA -
97 25700 1476 2009 36 M NO ABD PAIN BLEEDING PV UL 7X6X6 S&C GRANULOSA CELL TUMOR Reticulin-positive,Alpha Inhibin positive
98 27889 1503 2009 42 M NO ABD PAIN UL 5X4X4 C SEROUS CYSTADENOMA -
99 30639 1561 2009 30 M NO ABD PAIN UL 5X4X4 C LUTEAL CYST -
100 28983 1635 2009 26 M NO ABD.MASS UL 15X8X6 C MUCINOUS CYSTADENOMA -
101 30819 1641 2009 36 M NO BLEEDING PV UL 5X4X3 S&C ENDOMETRIOTIC CYST -
102 28677 1642 2009 48 M NO ABD.MASS UL 25X21X8 C MUCINOUS CYSTADENOMA -
103 32653 1806 2009 38 M NO ABD PAIN UL 6X5X3 C LUTEAL CYST -
104 32297 1828 2009 24 M NO ABD PAIN UL 7X5X3 C ENDOMETRIOTIC CYST -
105 32628 1865 2009 48 M NO ABD.PAIN BL 5X5X4 S&C FOLLICULAR CYST -
106 31633 1866 2009 50 M NO ABD.MASS ABD.PAIN UL 5X4X4 C DERMOID CYST -
107 34069 1912 2009 55 M NO ABD.MASS ABD.PAIN UL 20X10X8 S&C CLEAR CELL ADENOCARCINOMA PAS-Positive
108 32797 1918 2009 65 M NO ABD.PAIN UL 5X4X3 S&C SEROUS CYSTADENO FIBROMA -
109 29936 1978 2009 47 M NO ABD.MASS ABD.PAIN UL 6X6X6 S&C MIXED GERM CELL TUMOR AFP-Positive
110 31322 1983 2009 50 M NO ABD.PAIN UL 6X3X3 C SEROUS CYSTADENO FIBROMA -
111 34955 1986 2009 47 M NO ABD.PAIN BLEEDING PV UL 5X4X3 C ENDOMETRIOTIC CYST -
112 34948 2047 2009 50 M NO ABD.MASS UL 15X10X5 C MUCINOUS CYSTADENOMA -
113 34627 2061 2009 24 N NO ABD.PAIN BL 7X4X3 C DERMOID CYST -
114 36635 2062 2009 35 M NO ABD.MASS ABD.PAIN BL 18X14X4 S&C SEROUS CYSTADENOCA -
115 34618 2093 2009 66 M NO ABD.MASS ABD.PAIN UL 10X10X5 C DERMOID CYST -
116 37263 2104 2009 45 M NO ABD.MASS ABD.PAIN UL 28X21X11 C SEROUS CYSTADENOMA -
117 37652 2137 2009 45 M NO ABD.PAIN UL 5X5X2 C MUCINOUS CYSTADENOMA -
118 36934 2245 2009 39 M NO ABD.PAIN BLEEDING PV UL 6X4X4 S&C ENDOMETRIOTIC CYST -
119 37648 2271 2009 45 M NO ABD.PAIN UL 6X4X3 C SEROUS CYSTADENOMA -
120 39358 2272 2009 38 M NO ABD.PAIN UL 6X4X4 S&C ENDOMETRIOTIC CYST -
121 41895 2297 2009 60 M NO ABD.MASS ABD.PAIN UL 12X9X9  S  SEROUS  CYSTADENOCARCINOMA-PD WT-1 positive & CK 7positive
122 39877 2305 2009 35 M NO ABD.MASS UL 15X8X5 S FIBROTHECOMA Reticulin-positive
123 55271 2309 2009 33 M NO ABD.MASS UL 10X4X4 C SEROUS CYSTADENOMA -
124 41541 2368 2009 60 M NO ABD.MASS ABD.PAIN UL 10X8X8 C MUCINOUS CYSTADENOMA -
125 39883 2423 2009 66 M NO ABD.MASS UL 10X5X5 C MUCINOUS CYSTADENOMA -
126 44345 2502 2009 67 M NO ABD.MASS ABD.PAIN UL 9X5X3 S&C SEROUS CYSTADENO CARCINOMA -
127 44648 2512 2009 27 M NO ABD.MASS ABD.PAIN UL 13X8X4 S  SEROUS CYSTADENOCARCINOMA -
128 45300 2542 2009 32 M NO ABD.PAIN UL 6X4X4 C SEROUS CYSTADENOMA -
129 46653 2555 2009 60 M NO ABD.MASS UL 10X10X5 C MUCINOUS CYSTADENOMA -
130 45636 2575 2009 51 M NO ABD.PAIN UL 5X4X4 C DERMOID CYST -
131 46129 2691 2009 30 M NO ABD.MASS BLEEDING PV UL 8X8X7 C ENDOMETRIOTIC CYST -
132 57590 2754 2009 37 M NO ABD.MASS UL 10X6X6 C MUCINOUS CYSTADENOMA -
133 50237 61     2010 32 M NO ABD.PAIN UL 6X6X5 C ENDOMETRIOTIC CYST -
134 54032 108   2010 70 M NO ABD.MASS ABD.PAIN UL 8X7X7 S&C SEROUS CYSTADENO CA -
135 52648 115  2010 27 M NO ABD.PAIN UL 7X4X4 C ENDOMETRIOTIC CYST -
136 54958 140  2010 25 M NO ABD.MASS ABD.PAIN UL 11X9X4 C SEROUS CYSTADENOMA -
137 1140 197  2010 15 N NO ABD.PAIN BL 6X4X4 S&C DERMOID CYST -
138 3989 217 2010 42 M NO ABD.PAIN UL 8X4X4 C SEROUS CYSTADENOMA -
139 2748 271  2010 27 M NO ABD.MASS ABD.PAIN UL 12X7X5 S&C ENDOMETRIOTIC CYST -
140 6549 307  2010 23 N NO ABD.PAIN UL 6X3X3 C SEROUS CYSTADENOMA -
141 6713 310  2010 32 M NO ABD.MASS ABD.PAIN UL 10X6X3 C ENDOMETRIOTIC CYST -
142 2350 331  2010 40 M NO ABD.MASS UL 18X10X8 C MUCINOUS CYSTADENOMA -
143 7545 353  2010 27 M NO ABD.MASS UL 10X7X6 C SEROUS CYSTADENOMA -
144 6213 399  2010 50 M NO ABD.PAIN UL 9X6X3 C DERMOID CYST -
145 10907 513  2010 21 N NO ABD.MASS ABD.PAIN UL 22X16X8 S&C MIXED GERM CELL TUMOR AFP-Positive
146 10900 514  2010 30 M YES ABD.PAIN BLEEDING PV UL 7X5X2 C FOLLICULAR CYST -
147 8832 528  2010 38 M NO ABD.MASS ABD.PAIN BL 13X12X8 C MUCINOUS CYSTADENOMA -
148 9009 533  2010 40 M NO ABD.PAIN UL 4X3X3 S&C ENDOMETRIOTIC CYST -
149 11539 555  2010 45 M NO ABD.MASS ABD.PAIN UL 14X9X5 S SEROUS CYSTADENOCARCINOMA-PD WT-1 positive & CK 7positive
150 14364 592 2010 25 N NO ABD.MASS ABD.PAIN UL 9X4X4 S&C DERMOID CYST -
151 11306 620 2010 42 M NO ABD.MASS ABD.PAIN UL 16X9X5 C SEROUS CYSTADENOMA -
152 11470 627 2010 25 M NO ABD.MASS ABD.PAIN UL 20X18X5 C MUCINOUS CYSTADENOMA -
153 14465 636 2010 45 M NO ABD.MASS UL 5X5X5 C SEROUS CYSTADENOMA -
154 12212 710 2010 35 M NO ABD.MASS UL 5X5X4 C SEROUS CYSTADENOMA -
155 15619 747 2010 66 M NO ABD.MASS ABD.PAIN BL 6X5X5 S&C MUCINOUS CYSTADENO CARCINOMA CK 7 positive &CK 20 negative
156 14882 758 2010 54 M NO ABD.MASS ABD.PAIN UL 10X8X8 C MUCINOUS CYSTADENOMA -
157 12392 764 2010 55 M NO ABD.MASS ABD.PAIN UL 6X6X5 C SEROUS CYSTADENOMA -
158 17270 765 2010 27 M NO ABD.MASS UL 7X5X4 C DERMOID CYST -
159 17816 782 2010 30 M NO ABD.MASS ABD.PAIN UL 19X12X6 C SEROUS CYSTADENOMA-BL -
160 18350 809 2010 27 M NO ABD.MASS ABD.PAIN UL 14X9X5 C SEROUS CYSTADENOMA -
161 18836 872 2010 47 M NO ABD.MASS ABD.PAIN BL 9X5X5 S  KRUKENBERG TUMOR PAS-Positive
162 20507 986 2010 40 M NO ABD.MASS ABD.PAIN BL 11X5X5 S  SEROUS  CYSTADENOCARCINOMA-PD WT-1 positive & CK 7 Negative
163 23461 987 2010 40 M NO ABD.MASS UL 12X11X4 C SEROUS CYSTADENOMA -
164 23415 1024 2010 54 M NO ABD.MASS ABD.PAIN UL 22X19X10 S&C GRANULOSA CELL TUMOUR Reticulin-positive,Alpha Inhibin- positive
165 25141 1027 2010 20 N NO ABD.MASS ABD.PAIN UL 14X11X4 C SEROUS CYSTADENOMA -
166 22439 1056 2010 65 M NO ABD.MASS ABD.PAIN UL 6X6X6 S&C  SEROUS  CYSTADENOCARCINOMA-PD WT-1 positive & CK 7positive
167 19570 1082 2010 67 M NO ABD.MASS ABD.PAIN UL 11X10X7 S BRENNER TUMOUR -
168 20181 1145 2010 52 M NO ABD.MASS UL 9X6X6 S FIBROMA -
169 28213 1156 2010 40 M NO ABD.MASS ABD.PAIN UL 11X8X4 C SEROUS CYSADENOMA -
170 27725 1157 2010 25 M NO ABD.MASS UL 18X6X2 C SEROUS CYSTADNOMA -
171 26380 1196 2010 52 M NO ABD.MASS ABD.PAIN UL 18X10X5 C MUCINOUS CYSTADENOMA -
172 28559 1205 2010 62 M NO ABD.MASS ABD.PAIN BL 11X8X7 S&C SEROUS CYSATADENOCARCINOMA -
173 27004 1223 2010 27 M NO ABD.MASS UL 12X6X6 C LUTEAL CYST -
174 26834 1233 2010 50 M NO ABD.MASS ABD.PAIN UL 19X18X6 S&C SEROUS CYSTADENOCARCINOMA -
175 30494 1285 2010 52 M NO ABD.MASS ABD.PAIN UL 24X18X8 C MUCINOUS CYSTADENOMA -
176 28021 1340 2010 50 M NO ABD.MASS ABD.PAIN UL 20X17X10 C MUCINOUS CYSTADENOMA -
177 30513 1377 2010 52 M NO ABD.MASS ABD.PAIN UL 12X7X5 C SEROUS CYSTADENOMA -
178 30417 1390 2010 70 M NO ABD.MASS BLEEDING PV UL 12X11X8 S&C ENDOMETRIOTIC CYST -
179 31518 1449 2010 40 M NO ABD.PAIN UL 5X4X4 C SEROUS CYSTADENOMA -
180 31750 1471 2010 43 M NO ABD.PAIN UL 5X2X2 C DERMOID CYST -
181 32158 1479 2010 27 M NO ABD.MASS ABD.PAIN UL 9X5X5 C ENDOMETRIOTIC CYST -
182 34162 1509 2010 38 M NO ABD.PAIN UL 4X2X2 C LUTEAL CYST -
183 33860 1532 2010 55 M NO ABD.MASS ABD.PAIN UL 18X12X6 S&C SEROUS-BL TUMOR -
184 36277 1888 2010 50 M NO ABD.PAIN UL 5X3X3 C SEROUS CYSTADENOMA -
185 38600 1898 2010 53 M NO ABD.PAIN UL 6X4X2 C SEROUS CYSTADENOMA -
186 41423 2092 2010 40 M NO ABD.PAIN UL 7X4X3 C SEROUS CYSTADENOMA -
187 42535 2093 2010 35 M NO ABD.PAIN UL 7X6X5 C SEROUS CYSTADENOMA -
188 43826 2139 2010 66 M NO ABD.MASS ABD.PAIN BL 8X6X5 S &C MUCINOUS CYSTADENOCARCINOMA PAS-Positive,CK 7 positive &CK 20 negative
189 46182 2144 2010 45 M NO ABD.MASS ABD.PAIN UL 12X7X7 C SEROUS CYSTADENOMA -
190 43100 2204 2010 37 M NO ABD.MASS ABD.PAIN UL 12X9X3 C SEROUS CYSTADENOMA -
191 46982 2272 2010 23 N NO ABD.PAIN UL 7X6X5 C SEROUS CYSTADENOMA -
192 49383 2304 2010 15 N NO ABD.PAIN UL 7X5X4 C DERMOID CYST -
193 46547 2320 2010 66 M NO ABD.MASS ABD.PAIN BL 10X5X5 S&C  SEROUS  CYSTADENOCARCINOMA-PD WT-1 positive & CK 7positive
194 46991 2387 2010 48 M NO ABD.MASS ABD.PAIN BL 20X16X10 S&C MUCINOUS CYSTADENOCARCINOMA PAS-positive,CK 7 positive &CK 20 negative
195 51720 2403 2010 30 M NO ABD.MASS ABD.PAIN UL 9X7X6 C DERMOID CYST -
196 51680 2500 2010 24 M NO ABD.PAIN UL 5X5X4 C SEROUS CYSTADENOMA -
197 50731 2537 2010 32 M NO ABD.PAIN UL 7X5X5 C SEROUS CYSTADENOMA -
198 52896 2580 2010 47 M NO ABD.MASS ABD.PAIN UL 9X6X4 C SEROUS CYSTADENOMA -
199 57567 2581 2010 49 M NO ABD.MASS ABD.PAIN UL 8X7X5 S  SEROUS  CYSTADENOCARCINOMA-PD WT-1 positive & CK 7positive
200 54251 2592 2010 60 M NO ABD.MASS ABD.PAIN UL 17X6X4 C MUCINOUS CYSTADENOMA -
201 52282 2611 2010 45 M NO ABD.PAIN UL 9X7X3 C DERMOID CYST -
202 53929 2621 2010 27 M NO ABD.PAIN UL 7X4X2 C SEROUS CYSTADENOMA -
203 56058 2622 2010 40 M NO ABD.PAIN UL 7X6X4 C SEROUS CYSTADENOMA -
APPENDIX I 
PROFORMA 
NAME:                                                                                                                                                    
DATE: 
AGE: 
I.P NO/O.P NO: 
ADDRESS: 
BIOPSY NO: 
CLINICAL HISTORY: 
 Presenting complaints- 
 Menstrual history- 
 Marital history- 
 Parity- 
 Past history- 
H/O exogenous hormonal intake 
Previous clinical illness/surgery 
 Family history 
GENERAL EXAMINATION 
 Anaemia 
 Jaundice 
 Pedal edema 
 Generalised lymphadenopathy 
SYSTEMIC EXAMINATION 
 CVS 
 RS 
 ABDOMEN 
INVESTGATIONS: 
Blood investigations: 
 Hb 
 Serum markers-CA-125, AFP, HCG, Lipid profile, Thyroid 
function test 
Radiological examinations 
 USG - 
 CT - 
 MRI  - 
FNAC FINDINGS: 
CLINICAL DIAGNOSIS: 
SURGERY DONE: 
HISTOPATHOLOGICAL EXAMINATION: 
 Gross features 
 
 Microscopic features 
 
 
 Other studies 
 Special stain- 
 Immunohistochemical findings – 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 APPENDIX II 
Staining procedure: 
Periodic Acid Schiff stain: 
 Bring section to water 
 Rinse in distilled water 
 Treat with Periodic Acid solution for 5 min 
 Rinse in distilled water 
 Place in Schiff reagent for 15 min 
 Place in running tap water for 10 minutes for pink colour to 
develop 
 Stain in Harris haematoxylin for 6 minutes 
 Rinse in tap water 
 Differentiate in acid alcohol for 3-10 quick dips 
 Wash In tap water 
 Dip in lithium carbonate  
 Wash in tap water 
 Dip in alcohol 95% 
 Absolute alcohol 2 changes 
 Xylene 2 changes 
 Mount in DPX. 
  
Result 
 PAS positive substance-Magenta colour 
 Nuclei-Blue 
RETICULIN STAIN: 
 Bring sections to water 
 Potassium permanganate 1%  for 2 minutes. 
 Wash in tap water 
 1% oxalic acid for 3 minutes 
 Wash in water 
 Silver nitrate solution for 10 minutes 
 Rinse in distilled water for 10 seconds and in 10% formalin for 3 
minutes 
 Tone in goldchloride 0.1% for 10 minutes 
 1% Oxalic acid for 1 minute 
 1% sodium thiosulphate for 1 minute 
 Wash in water 
 Dehydrate in absolute alcohol 
 Clear in xylene 
 Mount in DPX 
Result : 
 Reticulin fibres-Black in colour. 
 
KEY TO MASTER CHART 
 
M  - MULTIPARITY 
N  - NULLIPARITY 
UL  - UNILATERAL 
BL  - BILATERAL 
ABD.MASS - ABDOMINAL MASS  
ABD.PAIN - ABDOMINAL PAIN 
SEROUS CYSTADENOCARCINOMA PD - 
SEROUS CYSTADENOCARCINOMA-POORLY 
DIFFERENTIATED TYPE 
SEROUS TUMOUR-BL - 
BORDERLINE SEROUS TUMOUR 
CK  - CYTOKERATIN 
EMA  - EPITHELIAL MEMBRANE ANTIGEN 
AFP  - ALPHA FETO PROTEIN 
PAS  - PERIODIC ACID SCHIFF 
WT-1  - WILMS TUMOUR ANTIGEN 
 
 
